Aus-CanPCRA Greetings

Welcome from the Director

On behalf of the Australian-Canadian Prostate Cancer Research Alliance I would like to welcome you to our 4th collaborative Symposium, proudly supported by the Queensland Government National and International Research Alliance Program and the Australian Prostate Cancer Research Centre – Queensland.

The Symposium hopes to bring together a wealth of knowledge, expertise, ideas and resources, in a format that encourages free flowing participation and collaboration, and facilitates exchange within the global prostate cancer community; with the goal of advancing translational outcomes.

Your contribution is invaluable to building the strength of this exciting and growing network and I look forward to your continued involvement with the Australian-Canadian Prostate Cancer Research Alliance!

Best wishes,

Professor Colleen Coyne Nelson
Director
Australian-Canadian Prostate Cancer Research Alliance

The Aus-CanPCRA Coordinators
Kathryn Arthy – Australian Coordinator
Kathleen Barilla – Canadian Coordinator

For detailed information on the Australian-Canadian Prostate Cancer Research Alliance please visit the Aus-CanPCRA website - www.aus-canprostatealliance.org

Acknowledgements

The Australian-Canadian Prostate Cancer Research Alliance acknowledges its partners and supporters:

Australian Prostate Cancer Research Centre Queensland www.australianprostatecentre.org

QUT ihbi Institute of Health and Biomedical Innovation www.ihbi.qut.edu.au

Princess Alexandra Hospital BRISBANE • AUSTRALIA www.health.qld.gov.au/pahospital

Australian Government Department of Health and Ageing www.health.gov.au

Prostate Cancer Canada www.prostatecancer.ca

Prostate Cancer Foundation of Australia www.prostate.org.au

Government of Canada / Gouvernement du Canada Canada www.canadainternational.gc.ca/australia-australie/index.aspx

Queensland Government Department of Science, Information Technology, Innovation and the Arts www.qld.gov.au

TRI partnering for better health www.tri.edu.au

VANCOUVER PROSTATE CENTRE www.prostatecentre.com

MOVEMBER FOUNDATION movember.com

CSIRO THE AUSTRALIAN eHEALTH RESEARCH CENTRE aehrc.com

Life Sciences Queensland www.lsq.com.au

Griffith UNIVERSITY Eskitis Institute for Cell and Molecular Therapies www.griffith.edu.au/science-aviation/eskitis-institute-cell-molecular-therapies

diamantina health partners Innovative healthcare through academic leadership www.diamantina.org.au

Contents

2013 Symposium Program at a glance

Time	Day 1: Wednesday August 14	Day 2: Thursday August 15	Day 3: Friday August 16	Day 4: Saturday August 17
Breakfast Available 6:30am – 9:00am		Hot and Cold Buffet Breakfast *Lagoons Restaurant*	Hot and Cold Buffet Breakfast *Lagoons Restaurant*	Hot and Cold Buffet Breakfast *Lagoons Restaurant*
8:00am – 9:00am		Poster Set-up *Mirage Ballroom*		
9:00am – 9:15am		Welcome *Mirage Ballroom*	Delegate Arrival and Settling In *Mirage Ballroom*	Delegate Arrival and Settling In *Mirage Ballroom*
9:15am – 10:00am		Session 1 - Stress in Treatment Resistance *Mirage Ballroom*	Session 7 - Next Generation Sequencing: Challenges and Opportunities for the Clinic *Mirage Ballroom*	Session 13 - Imaging *Mirage Ballroom*
10:00am – 10:45am		Session 2 - Targeting AR variants versus full length AR in CRPC *Mirage Ballroom*	Session 8 - Prostate Cancer Genomics *Mirage Ballroom*	Session 14 - Selected Poster Presentations *Mirage Ballroom*
10:45am – 11:15am		Morning Tea *Mirage Ballroom Foyer*	Morning Tea *Mirage Ballroom Foyer*	Morning Tea *Mirage Ballroom Foyer*
11:15am – 12:00pm		Session 3 - Metabolism and metabolics *Mirage Ballroom*	Session 9 - Epigenomics and Proteomics Biomarkers *Mirage Ballroom*	Session 15 - Where to from here - shared resources and opportunities *Mirage Ballroom*
12:00pm – 2:00pm	Symposium Registration Presentation File Handover (for speakers) *Mirage Ballroom Foyer* Poster Set-up *Mirage Ballroom*	Lunch *Lagoons Restaurant* Poster Session *Mirage Ballroom*	Lunch *Lagoons Restaurant* Poster Session *Mirage Ballroom*	Lunch *Lagoons Restaurant*
2:00pm – 2:45pm		Session 4 - Modelling Prostate Cancer *Mirage Ballroom*	Session 10 - Signalling Networks/Tumour Microenvironment *Mirage Ballroom*	
2:45pm – 3:30pm		Session 5 - CTCs *Mirage Ballroom*	Session 11 - Tumour Cell Plasticity *Mirage Ballroom*	
3:30pm – 4:00pm		Afternoon Tea *Mirage Ballroom Foyer*	Afternoon Tea *Mirage Ballroom Foyer*	
4:00pm – 4:45pm		Session 6 - Clinical Future of Prostate Cancer Applications *Mirage Ballroom*	Session 12 - Bioengineering, Nanotechnologies and Drug Screening *Mirage Ballroom*	
4:45pm – 5:30pm			Poster Collection *Mirage Ballroom*	
6:30pm – 10:30pm	Pre-dinner drinks *Gilligans Island* Welcome Dinner *Main Beach*	Dinner *Il Pescatore Restaurant & Terrace*	Farewell Dinner *Poolside Gazebo*	

Australian Prostate Cancer Research Centre Queensland

Queensland Government

Session 1: Stress in Treatment Resistance

9:15 – 10:00am

Chairs

Dr Jeff Holst
Associate Faculty
Centenary Institute
Nutrient stress induced resistance

Dr Amina Zoubeidi
Assistant Professor
Vancouver Prostate Centre
University of British Columbia
Stress induced oncogenic pathways

Speakers

Dr Martin Gleave
Director
Vancouver Prostate Centre
Stress induced ER stress and treatment resistance

Dr Andrew Trotta
Postdoctoral Research Officer
University of Adelaide
Stress co-chaperones as modulators of proliferation signalling

Dr Luc Furic
Research Fellow
Prostate Cancer Research Program, Monash University
Pharmacological stress induced activation of compensatory growth and proliferation pathways

Professor Rob Bristow
Clinician Scientist and Professor
Ontario Cancer Institute
Princess Margaret Cancer Centre, University of Toronto
Stress induced Hypoxia and treatment resistance

Session 2: Targeting AR variants versus full length AR in CRPC

10:00 – 10:45am

Chairs

Dr Paul Rennie
Director of Laboratory Research, Vancouver Prostate Centre
Professor, Urologic Sciences, University of British Columbia
New small molecule drugs that target ARV7



Professor Wayne Tilley
Director, Dame Roma Mitchell Cancer Research Laboratories
University of Adelaide
ARVs, CRPC and targeting the AR-NTD

Dr Martin Gleave
Director
Vancouver Prostate Centre
Targeting AR and ARVs with antisense oligonucleotides

Panel

Professor Anthony Costello
Head, Department of Urology, Royal Melbourne Hospital
Executive Director, Australian Prostate Cancer Research Centre Epworth
Professorial Fellow, Department of Surgery, University of Melbourne

Dr Mitchell Lawrence
Postdoctoral Fellow
Prostate Cancer Research Program
Monash University

Professor Simone Chevalier
Associate Professor
McGill Urology Director of Research
McGill University

Assistant Professor Amir Goldkorn
Assistant Professor of Medicine
Norris Comprehensive Cancer Centre, Keck School of Medicine
University of Southern California

Dr Elizabeth Hovey
Senior Staff Specialist
Prince of Wales Hospital

Professor Bill Watson
Associate Professor of Cancer Biology
University College Dublin

Session 3: Metabolism and metabolics

11:15am – 12:00pm

Chairs

Dr Jennifer Gunter
Postdoctoral Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute
Insulin in androgen-deprived prostate cancer cells

Dr Lorelei Mucci
Associate Professor
Harvard School of Public Health
Obesity and the TMPRSS2:ERG fusion: an example of precision patho-epidemiology

Speakers

Dr Niall Corcoran
Director of Translational Research
Australian Prostate Cancer Research Centre Epworth
University of Melbourne
The role of adipose tissue in prostate cancer progression

Dr Anthony Joshua
Clinician Scientist
Princess Margaret Cancer Centre
Metformin – hot or cold?

Professor Stephen Finn
Associate Professor of Pathology
University of Dublin
Trinity College
Obesity, inflammation and coagulation, the lethal trinity in Prostate Cancer Progression

Session 4: Modelling Prostate Cancer

2:00 – 2:45pm

Chairs

Professor Gail Risbridger
Head, Prostate Cancer Research Group
Deputy Dean-Strategic Projects, Faculty of Medicine, Nursing and Health Sciences
Research Director, Monash Comprehensive Cancer Consortium
Monash University

Dr YZ Wang
Senior Scientist
Vancouver Prostate Centre
British Columbia Cancer Agency
Associate Professor, University of British Columbia

Presentations will address two questions: 1. What is the preferred model of PC that you currently use? 2. In theory what would be the key features of your perfect model and what innovations are necessary to achieve this?

Speakers

Dr Martin Gleave
Director
Vancouver Prostate Centre

Dr Emma Beardsley
Clinical Fellow, Prostate Cancer Research Program, Monash University
Medical Oncologist, Frankston Hospital, Peninsula Health

Dr Renea Taylor
Research Fellow
Prostate Cancer Research Program
Department of Physiology
Monash University

Dr Luc Furic
Research Fellow
Prostate Cancer Research Program
Monash University



Dr Christopher Ong
Senior Scientist
Vancouver Prostate Centre

Session 5: CTCs

2:45 – 3:30pm

Chair

Professor Colleen Nelson
Executive Director
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Speakers

Professor Klaus Pantel
Professor and Director
Department of Tumour Biology
University Medical Center Hamburg-Eppendorf
Pushing the boundaries with new CTC capture and analysis technologies

Professor Stephen Finn
Associate Professor of Pathology
University of Dublin
Trinity College
Beyond counting, making CTCs work in the clinic

Assistant Professor Amir Goldkorn
Assistant Professor of Medicine
Norris Comprehensive Cancer Centre, Keck School of Medicine
University of Southern California
Incorporating new CTC technologies into clinical trials

Associate Professor Elizabeth Williams
Principal Research Fellow (Tumour Models)
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute
Impact of tumour cell plasticity on CTC capture



Professor Paul Li
Professor, Chemistry
Simon Fraser University
The Same Single Cell Bioanalyzer (SASCA) tracks the same single prostate cancer cell over a long duration: simultaneous optical observation and fluorescent measurement

Session 6: Clinical Future of Prostate Cancer Applications

4:00 – 4:45pm

Chair

Professor Colleen Nelson
Executive Director
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Panel

Dr Martin Gleave
Director
Vancouver Prostate Centre

Professor Anthony Costello
Head, Department of Urology, Royal Melbourne Hospital
Executive Director, Australian Prostate Cancer Research Centre Epworth
Professorial Fellow, Department of Surgery, University of Melbourne

Professor Rob Bristow
Clinician Scientist and Professor
Ontario Cancer Institute
Princess Margaret Cancer Centre
University of Toronto

Dr Marketa Skala
Visiting Medical Specialist
Royal Hobart Hospital

Dr Anthony Joshua
Clinician Scientist
Princess Margaret Cancer Centre

Dr Elizabeth Hovey
Senior Staff Specialist
Prince of Wales Hospital

Professor Stephen Finn
Associate Professor of Pathology
University of Dublin
Trinity College

Session 7: Next Generation Sequencing: Challenges and Opportunities for the Clinic

9:15 – 10:00am

Chairs

Dr Melanie Lehman
Postdoctoral Fellow
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute
The prostate cancer transcriptome: What are we missing?

Associate Professor Marcel Dinger
Head of the Centre for Clinical Genomics
Garvan Institute for Medical Research
Early detection and response monitoring of tumours by next generation sequencing. Possibilities and perspectives

Dr Paul Boutros
Assistant Professor, University of Toronto
Principal Investigator, Ontario Institute for Cancer Research
Whole-Genome Sequencing of FFPE Samples

Speakers

Professor Stephen Finn
Associate Professor of Pathology
University of Dublin
Trinity College
Taking next generation sequencing to the clinic

Professor Klaus Pantel
Professor and Director
Department of Tumour Biology
University Medical Center Hamburg-Eppendorf
Sequencing of Single Cells and CTCs

Dr Jeremy Clark
Senior Research Associate
University of East Anglia
RNA in Urine

Session 8: Prostate Cancer Genomics

10:00 – 10:45am

Chairs

Professor Rob Bristow
Clinician Scientist and Professor
Ontario Cancer Institute
Princess Margaret Cancer Centre, University of Toronto
ICGC prostate cancer sequencing

Professor Vanessa Hayes
Professor and Head of Human Comparative Genomics
Garvan Institute of Medical Research
Population genetics and prostate cancer risk

Speakers

Dr Janet Stanford
Member, Division of Public Health Sciences
Fred Hutchinson Cancer Research Centre
Genetic and epigenetic signatures for prostate cancer mortality

Dr Jacques Lapointe
Associate Professor
McGill University
CGH in prostate cancer prognosis

Dr Jyotsna Batra
Postdoctoral Fellow
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute
Prostate cancer GWAS: fine-mapping to function

Associate Professor Christopher Hovens
Scientific Director
Australian Prostate Cancer Research Centre Epworth
University of Melbourne
Genomic sequencing of metastasis vs primaries

Session 9: Epigenomics and Proteomics Biomarkers

11:15am – 12:00pm

Chairs

Professor Bharati Bapat
Professor
University of Toronto
Dynamic interplay between methylation and hydroxymethylation in prostate cancer

Distinguished Professor Judith Clements
IHBI Cancer Program Leader, Scientific Director APCRC-Q
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Speakers

Professor Stephen Pennington
Professor of Proteomics
University College Dublin
Assembly and Measurment of Blood Based Protein Biomarker for Prostate Cancer

Dr Bill Jordan
Director
Centre for Biodiscovery
Victoria University of Wellington
Prostate cancer protein discovery in the context of the Human Proteome Project

Dr Lorelei Mucci
Associate Professor
Harvard School of Public Health
Trichomonas vaginalis: a biomarker of aggressive prostate cancer?

Dr Ruth Pidsley
Postdoctoral Researcher
Garvan Institute of Medical Research
Prostate Cancer and the Epigenome

Dr Luke Selth
Research Fellow
University of Adelaide
A current perspective on microRNAs in body fluids as biomarkers of prostate cancer

Session 10: Signalling Networks/Tumour Microenvironment

2:00 – 2:45pm

Chairs

Professor Simone Chevalier
Associate Professor
McGill Urology Director of Research
McGill University
Consequences of Fer overexpression and activation in prostate cancer progression

Professor Adrian Herington
Associate Director IHBI (TRI)
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute
The Ghrelin Axis – does it have an appetite for prostate cancer

Speakers

Dr Sally Stephenson
Lecturer and Group Leader, Eph Receptor Biology Group
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute
EphB4 – an "eph"ective contributor to prostate cancer

Dr Kevin Wang
Research Officer
Centenary Institute
Integration of nutrient signalling and PI3K pathways in prostate cancer

Dr Grant Buchanan
Laboratory Head
University of Adelaide
Hic5 and AR signalling in the androgen response and adhesion of prostate fibroblasts

Distinguished Professor Judith Clements
IHBI Cancer Program Leader, Scientific Director APCRC-Q
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute
The KLK degradome and downstream signalling pathways in a prostate stromal microenvironment

Session 11: Tumour Cell Plasticity

2:45 – 3:30pm

Chairs

Professor Ralph Buttyan
Professor in Urologic Sciences and Senior Scientist
Vancouver Prostate Centre
University of British Columbia
Introduction, Intent and Goals of the Session

Associate Professor Elizabeth Williams
Principal Research Fellow (Tumour Models)
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute
Screening for Regulators of EMT

Speakers

Dr Brett Hollier
Senior Research Fellow, Queensland Smart Futures Fund Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute
Defining a Role for EMT in PCa Metastasis

Dr Amy Lubik
Postdoctoral Fellow
Vancouver Prostate Centre
Tumour Stems from Tumour Non-Stems

Dr Amina Zoubeidi
Assistant Professor
Vancouver Prostate Centre
University of British Columbia
Cell Plasticity as a Mechanism of Resistance to Enazalutamide

Session 12: Bioengineering, Nanotechnologies and Drug Screening

4:00 – 4:45pm

Chairs

Professor Dietmar Hutmacher
Professor and Chair of Regenerative Medicine, Medical Device Domain Leader
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute
in vitro model systems to study mechanisms of bone metastases

Dr Michael Doran
Group Leader - Stem Cell Therapies Laboratory
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute
Stem Cell Niche Recapitulation

Speakers

Dr Desmond Pink
Research Associate
University of Alberta
A cancer microparticle platform for enhanced prognosis of prostate cancer

Dr Boris Holzapfel
PhD Candidate
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute
Establishment of a novel xenograft model to study the homing sequence of human prostate cancer cells to engineered human bone

Professor Vicky Avery
Chief Investigator and Head
Discovery Biology
Griffith University

Dr Gaetano Zafarana
Research Associate
Princess Margaret Cancer Centre
STTARR Facility

Session 13: Imaging

9:15 – 10:00am

Chairs

Professor Pamela Russell
Head of Biomedical Imaging and Prostate Cancer Models
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute
Targeted hyperbranched polymers for 19F-MRI theranostics



Dr Christopher Ong
Senior Scientist
Vancouver Prostate Centre

Speakers

Professor Rob Bristow
Clinician Scientist and Professor
Ontario Cancer Institute
Princess Margaret Cancer Centre, University of Toronto
Tracking DNA Repair Following Chemotherapy and Radiotherapy In Situ



Dr John Lewis
Frank and Carla Sojonky Chair in Prostate Cancer Research
University of Alberta
EGFL7 as a novel target for molecular imaging of tumour neoangiogenesis



Dr Robert Paproski
Postdoctoral Fellow
University of Alberta
Nanodroplets: next generation ultrasound contrast agents for tumour imaging

Dr David Rivest-Henault
Postdoctoral Fellow
Australian e-Health Research Centre
Commonwealth Scientific and Industrial Research Organisation (CSIRO)
Advances in MRI-based radiation therapy treatment planning

Mr Kenneth Ng
Graduate Student
University of Toronto
Nanoparticles - Photoacoustic Imaging

Session 14: Selected Poster Presentations

10:00 – 10:45am

Poster Judges

Dr Manuel Altamirano-Dimas
Postdoctoral Fellow
Vancouver Prostate Centre

Dr Liesel FitzGerald
Research Fellow
Cancer Council Victoria

Dr Patrick Ling
Senior Research Fellow
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute



Dr Rose Martiniello-Wilks
Senior Lecturer and Head
Translational Cancer Research Group (TCRG)
School of Medical and Molecular Biosciences
University of Technology Sydney

Professor Bill Watson
Associate Professor of Cancer Biology
University College Dublin

Session 15: Where to from here - shared resources and opportunities

11:15am – 12:00pm

Chairs

Dr YZ Wang
Senior Scientist
Vancouver Prostate Centre
British Columbia Cancer Agency
Associate Professor, University of British Columbia

Professor Colleen Nelson
Executive Director
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Dr Manuel Altamirano-Dimas
Postdoctoral Fellow
Vancouver Prostate Centre

Dr Altamirano-Dimas is a Research Fellow working in prostate cancer research at Dr Michael E Cox's laboratory, performing bioinformatics analysis is several studies. Dr Cox's lab's projects include the response of prostate cancer to growth factors during development of castration-resistant prostate cancer, under the influence of insulin-like growth factor (IGF) and kinase signalling. In collaboration with colleagues from Antisence Therapeutics, Melbourne, Australia, they are assessing the use of antisense therapeutic modalities targeting the IGF axis to see how these agents, alone or in combination with conventional chemotherapeutic agents, impact growth and survival signalling in androgen-dependent and CRPC model.

While the cause of prostate cancer is unknown, the fusion of TMPRSS2 with members of the ETS family, including ETV1 and mainly ERG, have been found frequently in prostate cancer patients, and is associated with poor prognosis, specifically if there is mutation in PTEN. They have developed a panel of lineage-matched non-transformed and ERG transformed prostatic epithelial cell lines, and are testing the hypothesis that aberrant ERG expression consistently reprograms gene expression patterns in prostatic epithelial cells causing transformation, accelerated growth, invasion and enhanced metastatic potential.

They are assessing how, in normal prostate epithelial cells, ERG induces expression of stem cells through epigenetic modifications that lead to genetic changes which in turn lead to down regulation of tumour suppressor genes. The modified system has neoplastic characteristics, including cell proliferation, invasion, and is associated with alterations in the androgen receptor signalling. These studies will set the benchmark for understanding how ERG causes prostate cancer and identify diagnostic and therapeutic targets.

Dr Jiyuan An
Postdoctoral Fellow
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Dr An received his PhD and Masters degree in computer science from University of Tsukuba and Kyushu Institute of Technology, Japan. In his current role, he is engaged in discovering significant non-coding genes from microarray and sequencing data. He also creates mathematical models for biological data, and finds the most suitable parameters for the models.

Dr An and his colleagues recently focussed on the high rate of false positive rates in current miRNA target prediction tools. This renders identification of co-regulating groups of miRNAs and target genes unreliable. They devised a procedure to identify highly probable co-regulating miRNAs, and the corresponding co-regulated gene groups, using a sequence of statistical tests to: (1) identify genes that are highly probable miRNA targets; (2) determine for each gene, the minimum number of miRNAs that co-regulate it with high probability; (3) find, for each gene, the combination of the determined minimum size of miRNAs that co-regulate it with the lowest p-value; and (4) discover for each such combination of miRNAs, the group of genes that are co-regulated by these miRNAs with the lowest p-value computed based on GO term annotations of the genes.

Professor Vicky Avery
Chief Investigator and Head
Discovery Biology
Griffith University

Professor Avery is a research scientist specializing in high through-put and high content screening in an industry environment. During the last 14 years, she has made significant contributions within the field of Drug Discovery, resulting in the identification of new lead compounds and techniques, as well as necessitating the management of complex international research collaborations. At Active Biotech AB, Sweden (1998-2004), she led a project to identify the molecular target of 'Laquinimod', a novel oral treatment for relapsing multiple sclerosis in clinical trials. She was responsible for the development of assays for FDA to assess efficacy of a cholera vaccine, plus designed and developed assays to identify immuno-modulatory compounds against CD80, which led to RhuDex®, an oral treatment for RA in clinical trials.

As Head of Lead Discovery Biology (AstraZeneca /Griffith University collaboration), she has directed more than 50 HTS campaigns (2004-2007), spanning all disease areas and encompassing a diverse range of technologies. This number now exceeds more than 75 HTS campaigns. In addition to commercial drug discovery activities, Discovery Biology has successfully designed and implemented HTS assays for Malaria (MMV) and Trypanosomiasis (DnDi). They were awarded MMV Project of the Year (2007) for their innovative use of technology to identify new anti-malarial compounds. Her laboratory is now recognised as the MMV Global Screening Centre for Malaria Drug Discovery.

Professor Avery is the Programme Leader for Bioactive Discovery within the CRC for Cancer Therapeutics, playing an integral role in the translation of basic science to the clinic. Her laboratory has developed automated / high through-put approaches for evaluating cells grown in 3D and imaged in both 2D and 3D. These systems play a valuable role in analysing the impact of compounds on a variety of parameters in the 3D environment. In 2009, Discovery Biology received the Griffith University Pro-Vice Chancellor's Research Excellence Award for a Research Group .

Professor Bharati Bapat
Professor
University of Toronto

Professor Bapat's research program is focused on translational genomics - specifically discovery and functional characterization of cancer biomarkers and their applications to clinical setting. A major area of current research is investigation of epigenetic markers of genitor-urinary and gastro-intestinal neoplasms using genome-wide interrogation strategies. Using an integrated, multidisciplinary approach, her lab has discovered novel epigenetic biomarkers of prostate cancer, and provided insight into their potential utility as diagnostic and / or prognostic markers.

Related studies address functional significance of selected candidate genes and their epigenetic regulation in normal and disease states. Emerging initiatives are focused on the investigation of unique genetic and novel epigenetic profiles that will provide potential targets for therapeutic intervention, using genome-wide profiling and high-throughput technologies as well as pathway-based approaches.

The ultimate goal of Dr Bapat's research is to translate findings into clinical practice by working with physician researchers and clinicians, to develop a personalized medicine approach to improve patients' health and well-being.

Dr Jyotsna Batra
Postdoctoral Fellow
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Dr Batra obtained her PhD in India (2008) in molecular human genetics. She received NHMRC Peter Doherty fellowship in 2011 and is currently working as Research Fellow and Group leader at the newly established Translational Research Institute.

Dr Batra has extensive experience in genetics of complex disorders, where she specialises in identification of genetic polymorphisms that predispose to prostate cancer risk and prognosis. She has contributed to large scale consortium efforts including Indian Genome Variation consortium and the largest prostate cancer consortium, PRACTICAL.

She has published in journals such as Nature Genetics, Science, and PNAS though her significant role in consortium activities.

The major focus of her group is to understand the molecular mechanism behind the genetic associations identified through various genome-wide and candidate gene association studies.

Dr Emma Beardsley
Clinical Fellow, Prostate Cancer Research Program, Monash University
Medical Oncologist, Frankston Hospital, Peninsula Health

Dr Beardsley completed a clinical fellowship (genitourinary and Prostate) and working as a medical oncologist at The British Columbia Cancer Agency, Vancouver, Canada. Upon returning to Australia, she commenced practice as a Medical Oncologist with special interest in Prostate and Genitourinary malignancies at both Public and Private Medical Facilities.

She is particularly interested in clinical trial work, which enables lab research to move forward into the clinical settling, provides patients with an opportunity to try medications otherwise unavailable to them, and provides clinicians with firsthand experience in managing these new agents.

Working with Prof Gail Risbridger and her team at Monash, her focus has been on xenografting Castrate Resistant Prostate Cancer. Her aim is to continue to bridge the gap between scientists and clinicians.

Dr Beardsley is particularly interested in improving the understanding of mechanisms involved in prostate cancer progression and targeting treatment towards these mechanisms, while minimising toxicity and maintaining quality of life in patients and their families affected by prostate cancer.

Dr Tarek Bismar
Associate Professor
University of Calgary

Dr Bismar performed his medical studies in Syria, where he received his MD from Damascus University. He continued his postgraduate education at several US universities, including Washington University in St. Louis, Wayne State University in Michigan and Harvard University in Massachusetts.

Dr Bismar specialized in pathology at Washington University in St. Louis. During his studies, he decided to continue his training in urological pathology and start his own prostate cancer research program.

In addition to Dr Bismar's current role, he also supervises two post-doctorate candidates in the field of pathology.

Dr Bismar has also received the PCF Young Investigator Award, and the Junior I Scientist Award from the Fonds de la Recherche en Santé du Québec. He has authored 38 publications and book chapters. He is also a reviewer for scientific journals, such as Cancer Research, Clinical Cancer Research, and Cancer.

Dr Paul Boutros
Assistant Professor, University of Toronto
Principal Investigator, Ontario Institute for Cancer Research

Dr Paul Boutros pursued his undergraduate education in Chemical Engineering and Chemistry at the University of Waterloo. During the co-op portion of his degree he worked for a wide range of companies, including the Federal Government, a water-purification company, and Petro-Canada. However, he found his true calling during a work-term spent at Michigan State University developing computer models of drug response and his undergraduate thesis focused on modelling DNA damage. For this work, he was awarded First Place at the National Undergraduate Chemistry Conference.

In 2004, Dr Boutros started his PhD at the Ontario Cancer Institute in Toronto. During this time, he received several awards, including the CIHR/Next Generation First Prize and the Invitrogen Canada Young Investigator Silver Award.

Dr Boutros was awarded a PhD in 2008 for his work on cancer biomarkers, and started his independent research career with an appointment at the Ontario Institute for Cancer Research.

Today his research group focuses on using new DNA sequencing technologies to improve diagnosis and treatment of prostate cancer.

In particular, Dr Boutros is involved with the Canadian Prostate Cancer Genome Network (CPC-GENE), a national Outcomes-Based project focusing on developing biomarkers to predict those intermediate-risk prostate cancer patients who will suffer relapse, and those who can safely be placed on active surveillance protocols.

Additionally, he works on a number of experimental and algorithmic approaches to generating robust biomarkers, particularly in a non- or minimally-invasive fashion, as by using blood or urine.

Professor Rob Bristow
Clinician Scientist and Professor
Ontario Cancer Institute
Princess Margaret Cancer Centre
University of Toronto

Dr Bristow is a Clinician-Scientist and Professor within the Departments of Radiation Oncology and Medical Biophysics at the University of Toronto; a Senior Scientist at the Ontario Cancer Institute; and a Radiation Oncologist in Genitourinary cancers at the Princess Margaret Hospital.

His research interests include DNA damage signalling and repair, prostate cancer progression and prediction of prostate cancer treatment response.

Dr Bristow has active research programs and clinical trials pertaining to hypoxic cell targeting, use of synthetic lethality approaches to cancer treatment and combined molecular targeting with chemotherapy or radiotherapy.

He is the Editor of the 4th Edition Basic Science of Oncology, and has twice been a Canadian Foundation for Innovation (CFI) Award recipient. He has over 200 published papers, abstracts and book chapters, and has been an Invited Speaker or Visiting Professor on more than 80 occasions.

Dr Grant Buchanan
Laboratory Head
University of Adelaide

Dr Buchanan completed his undergraduate studies in Biochemistry at the University of Tasmania in 1992, his honours degree in Molecular Biology from the University of Adelaide in 1993, and a PhD in Cancer Research jointly at the Flinders University of South Australia in 2002.

His postdoctoral research at the University of Adelaide and the University of Southern California was in high-throughput technology and bioinformatics applied to cancer.

Dr Buchanan's Molecular Ageing Laboratory Group initiated in 2009 at the University of Adelaide is applying these skills to a deeper understanding of steroid receptors in the cancer microenvironment.

Specifically, his group is looking at how the co-ordinated action of steroid hormones in different compartments of the breast and prostate (e.g. stromal and epithelial cells) control maintenance and homeostasis of these tissues, and how this control breaks down in cancer, ageing and under conditions of hormone intervention. Techniques applied include molecular and cellular biology, next-generation sequencing, bioinformatics, chromatin immunoprecipitation (ChIP), ChIP-sequencing, cloning, expression microarray analysis, high-throughput transcriptional assays, siRNA knockdown, immunoblot analysis, drug screening, confocal microscopy, cellular signaling and novel animal models.

Professor Ralph Buttyan
Professor in Urologic Sciences and Senior Scientist
Vancouver Prostate Centre
University of British Columbia

Dr Ralph Buttyan is a Senior Scientist in the Vancouver Prostate Centre and has been involved in prostate cancer research for over 28 years. He joined the Vancouver Prostate Centre from New York, USA, where he was Professor in Pathology and Urology at Columbia University and a Senior Scientist at the Ordway Research Institute. He is a Past-President of the Society of Urological Research and remains on the Executive Board.

Dr Buttyan's research interest lies in understanding the molecular and genetic changes that enable prostate cancer cells to acquire resistance to androgen ablation (hormone) and other types of therapies.

More recently, his focus has turned to the role of developmental signalling pathways in therapeutic resistant of prostate cancer. This new work supports the ideas that cell signalling pathways that guide normal embryonic development of the prostate gland are hijacked in prostate cancer cells and become linked to the processes that drive the abnormal growth of the cancer cells and their ability to metastasize to other tissues of the body.

These abnormal embryonic signals appear to be also especially important for the acquisition of therapy resistance by prostate cancer. One potential benefit of this observation is the availability of contemporary drugs that selectively inhibit developmental signalling pathways, and Dr Buttyan's goal is to conduct pre-clinical tests on them as therapeutics for advanced prostate cancer.

Dr Mark Buzza
Program Manager - Global Action Plan
Movember

Dr Buzza is the Program Manager at the Movember Foundation where he oversees a global cross-functional collaborative research consortium, the Global Action Plan (GAP) Program. This program is designed to realize synergies within the global prostate cancer research effort and expedite outcomes for the benefit of prostate cancer patients. GAP aims to facilitate international collaboration between the world leading oncologists, urologists, pathologists, radiologists and researchers to jointly address key clinical challenges that accelerate research breakthroughs to optimize patient treatment decisions.

He has a broad background in medical and clinical research, biotechnology, pharma, not-for-profit and healthcare services and has held senior management roles within these sectors. He has also worked on strategy development and implementation initiatives with multinational organisations as a management consultant.

Dr Buzza has an extensive background in program delivery, market intelligence, business process improvement, stakeholder management, business analysis and planning, and strategy development and implementation and his specialty is to work with Boards and Executive Leadership Teams to deliver large complex strategic initiatives.

Dr Buzza has a PhD in Molecular Medicine from the University of Melbourne, an Executive MBA (with distinction) from the RMIT Graduate School of Business and Law and is an internationally certified PRINCE2 Project Management Practitioner.

Professor Simone Chevalier
Associate Professor
McGill Urology Director of Research
McGill University

Prof Chevalier's lab focuses on protein kinases linked to the growth and migration of PCa cells as well as on the paracrine regulation of their activation by neuroendocrine (NE) cell products found in the tumor cell microenvironment.

Their studies on similar mechanisms being up-regulated in normal basal/stem cells when induced to grow under androgen deprivation support the contribution of stem cells in PCa. Accordingly, strategies (gene therapies) are being developed to counteract these mechanisms in view of therapeutic applications in PCa.

Altogether, it is their firm belief that meaningful advances and discoveries on these mechanisms will lead to the development of new and specific diagnostic tools and therapeutic targets to control selectively the androgen-independent tumor cell subpopulations in PCa.

Dr Choi-Fong Cho
Postdoctoral Fellow
University of Alberta

Dr Cho is a post-doctoral fellow at the University of Alberta (Department of Oncology), and will be assuming a new post-doctoral position at the Brigham and Women's Hospital, Harvard Medical School (Department of Neurosurgery) in January 2014.

Dr Cho received her PhD in January 2013 at the University of Western Ontario (Department of Medical Biophysics). Her research focused mainly on non-invasive targeting of cancer to facilitate early diagnosis and directed therapeutics.

During the early stages of her PhD, Dr Cho focused her efforts on developing new strategies to screen one-bead-one-compound (OBOC) peptide libraries to enable rapid and accurate identification of novel affinity peptide ligands against specific cancer biomarkers.

In addition to screening against purified protein, Dr Cho has also designed a high throughput approach to efficiently identify novel affinity ligands from screening OBOC libraries against live cells.

Together with Dr John Lewis (Dept of Oncology, University of Alberta) and Dr Leonard Luyt (Dept of Chemistry, University of Western Ontario), Dr Cho used the screening approaches described above to discover several peptides with high binding affinity for an angiogenesis marker, a protein known as EGFL7.

They showed that fluorescent peptides were taken up and retained by cancer cells expressing the target protein on their cellular surface compared to control peptides. These peptides were incorporated onto fluorescent viral nanoparticles for applications in fluorescence microscopy and drug delivery (in collaboration with the laboratory of Dr Steinmetz at Case Western Reserve University).

Dr Cho demonstrated that EGFL7-targeted nanoparticles exhibited higher accumulation in fibrosarcoma tumors and their blood vessels compared to control nanoparticles using xenograft tumor models in both mice and chicken embryos. These peptides could serve as promising diagnostic tools for non-invasive detection of early cancer development.

Ms Ashlee Clark
PhD Candidate
Prostate Cancer Research Program
Monash University

Ms Clark is a first year PhD candidate under the supervision of Professor Gail Risbridger and Dr Renea Taylor at Monash University.

Her current research looks at prostate cancer cells that are able to survive after castration. The aims of her research are to characterise these cells using a xenografting model of human prostate cancer and to further understand how they differ from the tumour bulk.

Dr Jeremy Clark
Senior Research Associate
University of East Anglia

Dr Clark has 30 years of experience in cancer research. Through his research, he has identified eight oncogenes, three of which were previously undiscovered novel genes. These oncogenes are implicated in the development of a range of cancer types. Seven of the eight oncogenes have been patented for use in tumour diagnosis and management.

Dr Clark's current interests are searching for biomarkers that will predict the presence and prognosis of prostate cancer. Recently, in collaboration with Johann de Bono, he has discovered that prostate cancer patients' bloods contain an Affymetrix expression signature that is highly linked with patient survival (HR 4.5, p=0.0002) and alterations in the host immune system.

His current research at the University of East Anglia is centred on the discovery of diagnostic and prognostic markers for prostate cancer in urine samples. These investigations involve the harvesting of RNA from cells and secreted microvesicles (exosomes) for analysis by TaqMan microfluidic chips and NanoString.

Dr Clark and his co-workers are currently analysing a pilot of 100 active surveillance exosomal RNA samples analysed by TAQman microfluidic chips at the Royal Marsden Hospital and the Institute of Cancer Research. They are processing around 300 further samples obtained from the Norfolk and Norwich University Hospital for NanoString expression analysis.

Dr Clark also coordinates a Movember GAP initiative on urine analysis in prostate cancer patients. This involves processing urine samples for coordinated analysis by a number of groups worldwide for cell pellet and exosome mRNA expression, cell pellet DNA Methylation patterns, and urine proteins. Data streams will then be integrated for improved assessment of predictive and prognostic biomarkers in urine.

Distinguished Professor Judith Clements
IHBI Cancer Program Leader, Scientific Director APCRC-Q
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Since 1997, Professor Clements has lead the Cancer Research Program at QUT, that aims to more clearly understand the molecular and cellular basis for the development, progression, and metastasis of solid tumours.

Her own research program is focused on the role of the Kallikrein-related serine proteases in the progression of prostate and ovarian cancers. To this end, she applies a comprehensive systems biology approach using proteomic (substrate identification) and transcriptome (downstream signalling pathways) analysis in combination with 3D *in vitro* models to better reflect the *in vivo* tumour microenvironment.

Professor Clements is also the Scientific Director at the Australian Prostate Cancer Research Centre – Queensland, a dedicated prostate cancer research centre that comprises collaboration between QUT and the Princess Alexandra Hospital.

Prof Clements is a two-time winner of the Alban Gee Prize from the Urological Society of Australasia, and has also been the recipient of the QUT Faculty of Science Distinguished Award for Excellence in Research as well as the QUT Vice Chancellor's Award for Research Excellence. She is Chair of the Prostate Cancer Foundation of Australia (PCFA) Queensland Board and a member of the national PCFA Board.

Prof Clements was awarded the Queensland Women in Technology Biotech Outstanding Achievement Award for 2012, and has been recently awarded with the title of Distinguished Professor.

Dr Niall Corcoran
Director of Translational Research
Australian Prostate Cancer Research Centre Epworth
University of Melbourne

Dr Corcoran completed his studies (MB BCh BAO) at the University College of Dublin in 1998 and was awarded a PhD from the University of Melbourne in 2006. He is a urological surgeon and research scientist with an interest in the molecular drivers of lethal prostate cancer and novel treatments.

Professor Anthony Costello
Head, Department of Urology, Royal Melbourne Hospital
Executive Director, Australian Prostate Cancer Research Centre Epworth
Professorial Fellow, Department of Surgery, University of Melbourne

Professor Costello was the first urologist to use lasers to treat benign prostatic hyperplasia and has had international recognition in this field. He established an international urologic-oncology fellowship program commencing in 1991, where more than 30 fellows from all parts of the world have come to study postgraduate urologic-oncology surgery.

The only Australian member of the prestigious American Association of Genitourinary Surgeons, he is also an invited member of the International Advisory Board of the Cleveland Clinic Urological Department. In addition, Prof Costello is a national board member of the Australian Prostate Cancer Foundation.

In 2005, he developed a novel biological treatment of hormonal refractory prostate cancer, which is currently being trialed in phase I treatment for men with hormonal refractory prostate cancer and will soon be internationally trialed as a treatment for prostate cancer against conventional therapy.

In 2007, Prof Costello established the Victorian Prostate Cancer Research Collaborative, a network of research institutes interested in prostate cancer research housed at The Royal Melbourne Hospital.

Prof Costello has over 120 peer reviewed published articles and five book chapters in press and continues to innovate and lead initiatives in genito-urinary cancer research at The Royal Melbourne Hospital.

His current interest is in the development of drug treatment for prostate cancer and in clinical application of robotics in prostate cancer surgery. He heads the largest robotic surgery program in Australia and is one of four urologists invited to teach the technique of robotic prostatectomy for prostate cancer surgery at the American Association of Urological Surgery Annual General Meeting.

Sally Crittenden
Business Development Manager
Australian Prostate Cancer Research

Ms Crittenden's expertise is in fundraising, operations, and business development. She experience in the commercial and non-profit sectors, both in Australia and overseas.

In addition to her work for a number of organisations in the not-for-profit sector (including The Big Issue, Able Australia, and National Breast Cancer Foundation), Ms Crittenden was involved in the Olivia Newton John Cancer Appeal at the Austin. She was also responsible for fundraising activity for the new cancer centre that opened in 2011.

Ms Crittenden spent more than ten years in the major event industry and was responsible for the operations at major events, including the 2006 Commonwealth Games, Australian Grand Prix, and the National Mothers Day Classic Breast Cancer Walk/Run.

Since 2010, Ms Crittenden has been involved in the development of Australian Prostate Cancer Research, a new national research organisation, launched in 2012, which partners with leading institutions to develop, fund, and deliver national prostate cancer research programs.

Dr Tanya Day
Postdoctoral Researcher
Adelaide Prostate Cancer Research Centre
University of Adelaide

Dr Day undertook studies for a Bachelor of Biotechnology (Hons) at Flinders University, where she also subsequently completed her PhD in Radiation / Molecular Biology, investigating the molecular changes that occur as a result of radiation-induced DNA damage and the relevance of these changes to the development of cancer.

Studies performed as part of her PhD made significant contributions to the field of low dose radiation research, and resulted in the publication of eight manuscripts.

Dr Day's first postdoctoral period was spent at The Prostate Centre at Vancouver General Hospital, with Professor Martin Gleave, investigating the pro-and anti-apoptotic role of clusterin splice variants in prostate cancer. She now works with Professor Wayne Tilley at the Dame Roma Mitchell Cancer Research Centre at Adelaide University, investigating the role of aberrant AR-signalling in modifying gene expression in prostate cancer development.

Dr Day's research interests also include epigenetics, development of gene signatures, DNA damage-induced molecular changes in cancer and bioinformatics.

Dr Elena De-Juan-Pardo
Senior Postdoctoral Research Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Dr De-Juan-Pardo is a Materials Engineer with experience in development of biomaterials and *in vitro* models for tissue engineering, regenerative medicine, and cancer research.

In the past she has worked at Prof Kumar's laboratory (University of California at Berkeley) on engineering the microenvironment of the glioblastoma multiforme and the natural neural stem cell niche.

She has also worked at CEIT (San Sebastian, Spain), on the developed of *in vitro* 2D and 3D platforms for the study of cell migration and cell-matrix interactions in engineered microenvironments.

In January 2013 she joined Prof Dietmar Hutmacher's group at Queensland University of Technology (Brisbane, Australia). Dr De-Juan-Pardo's current research aims to develop an *in vitro* system that recapitulates the prostate tumour biology using primary human cells, bioreactors, and biomaterials.

Overall, her current research interests are focused on the study of the interactions between cells and the surrounding microenvironment, the development, and characterization of new biomaterials and biofabrication technologies and the development of 2D and 3D *in vitro* controlled models for tissue engineering and cancer research.

Associate Professor Marcel Dinger
Head of the Centre for Clinical Genomics
Garvan Institute for Medical Research

Marcel Dinger is the Head of the Centre for Clinical Genomics at the Garvan Institute of Medical Research. In this role, he brings together his combination of skills in informatics, genome biology, and business to establish a world-class genomics facility. His long-term objective is to realise the enormous potential of clinical genomics on healthcare in Australia.

Dr Dinger also Heads a research lab that focuses on the application of cutting-edge, next generation sequencing technologies to better understanding the earliest molecular events that occur in the onset of cancer. This approach has identified numerous novel regulatory molecules that are currently the subject of high-throughput functional screening.

Dr Dinger has worked in informatics and genomics since 1998 in both commercial and academic capacities. Attracting more than 2,800 citations (H-index 23), he has (co)-authored 42 papers, many of which appear in high profile life sciences journals.

Dr Dinger has been an invited speaker, both nationally and internationally, and is recipient of several highly competitive awards and fellowships, including an NHMRC Career Development Award and a Queensland Government Smart Futures Fellowship

Dr Michael Doran
Group Leader - Stem Cell Therapies Laboratory
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Dr Michael Doran completed a BSc (Genetics) and BEng (Chemical) at the University of Alberta in Canada. His passion for biomedical research motivated him to relocate to Sydney, Australia, and undertake a PhD in Biomedical Engineering.

Under the supervision of Dr Robert Nordon (UNSW), his PhD contributed to the development of a now-commercialized bioreactor for stem cell expansion. The bioreactor developed through Dr Doran's PhD was integrated with CaridianBCT's dialysis robotics platform and details on this product can be found at: http://www.terumobct.com/location/emea/products-and-services/Pages/Quantum-Cell-Expansion-System.aspx.com/quantumsystem/. While the commercial nature of the project did restricted publications, Dr Doran has filed one patent.

Following his PhD (2006), Dr Doran completed two postdoctoral fellowships, split between the University of Queensland (UQ) and the Mater Medical Research Institute (MMRI). During this time, he filed two more patents, mentored postgraduate students, published a number of high-impact papers, won UniQuest Trailblazer Innovation awards in three consecutive years, won four external competitive grants, and presented internationally at a number of conferences.

In 2010, Dr Doran relocated to QUT and was awarded the prestigious QUT Vice Chancellor's Fellowship. Dr Doran is a group leader, and his Stem Cell Therapies Laboratory is situated at the Translational Research Institute (TRI) on the Princess Alexandra Hospital campus. Since 2009 Dr Doran has published 24 articles, two of which are book chapters, has won seven external CIA grants, and two CIB NHMRC Project Grants. Dr Doran was awarded an on-going position at QUT in 2012.

Dr Jonathan Dunne
Prostate Cancer Postdoctoral Fellow
Victoria University of Wellington

Dr Dunne is a molecular biologist with a particular interest in mass spectrometry and proteomics. He completed his PhD in Cell and Molecular Bioscience at Victoria University of Wellington (VUW), using proteomics to examine the fibrolytic enzyme system of a prevalent rumen bacterium.

Dr Dunne is currently working as a Postdoctoral Fellow in the Bill Jordan laboratory at VUW, where the goal of his research is to identify proteins present within prostate cancers that can be used to predict the subsequent behaviour of the tumour.

Dr Stuart Ellem
Research Scientist
Prostate Cancer Research Program
Monash University

Dr Ellem obtained his PhD in 2006 from Monash University and currently works within the Department of Anatomy and Developmental Biology at Monash University, Australia.

His research program examines oestrogen synthesis and action in the prostate, particularly the opposing roles of the oestrogen receptors (ERa and ERb) and the emerging link between aberrant oestrogen exposure, inflammation, and prostate cancer.

His work is underpinned by transgenic mouse models and complemented by human clinical tissues and *in vitro* cell studies.

Dr Ellem's research has been supported by National and International funding bodies, including the NHMRC, Victorian Cancer Council, the United States Department of Defense, and the Prostate Cancer Foundation of Australia.

Professor Stephen Finn
Associate Professor of Pathology
University of Dublin
Trinity College

Dr Stephen Finn is an Associate Professor, Consultant Pathologist and Principal Investigator at The University of Dublin, Trinity College and at St James's Hospital Dublin (the latter is a tertiary referral cancer institution). He is also Director of the Cancer Molecular Diagnostic Laboratory; the only fully accredited molecular diagnostic laboratory in Ireland and the largest. Dr Finn's clinical practice focuses on Urological and molecular pathology. He is a former Senior Scientist and Staff Pathologist to the Centre for Molecular Oncologic Pathology at the Dana Farber Cancer Institute, Boston, USA, and is a member of the Irish Prostate Cancer Research Consortium (PCRC).

A current recipient of the Prostate Cancer Foundation Young Investigator Award, Dr Finn is also Co-PI on a current PCF Challenge Award. Dr Finn has research interests in the following areas: patho-epidemiology of prostate cancer, obesity and diet related to prostate cancer outcome, Circulating Tumour Cells in Prostate Cancer (Movember-funded), non-coding RNA and stem cell signatures in aggressive prostate cancer.

Dr Liesel FitzGerald
Research Fellow
Cancer Council Victoria

Dr FitzGerald obtained a PhD on the molecular genetics of familial prostate cancer from the University of Tasmania in 2007.

From late 2007 to 2011, she joined the Fred Hutchinson Cancer Research Centre as a post-doc for Dr Janet Stanford. Here she studied the genetics of both sporadic and familial prostate cancer, gaining additional experience in genetic epidemiology.

In November 2012, Dr FitzGerald joined the Cancer Council Victoria as the inaugural David Hill Research Fellow, where she works with Graham Giles and Gianluca Severi on several of their prostate cancer studies.

Dr FitzGerald's main research focus is on the identification of genomic predictors for aggressive and fatal forms of prostate cancer. As a part of her research program, she will be utilising their tumour tissue resource to identify diagnostic epigenetic and protein biomarkers that distinguish benign from fatal disease.

Dr Luc Furic
Research Fellow
Prostate Cancer Research Program
Monash University

Dr Furic obtained his PhD from University of Montreal for his work on RNA-protein interactions and mRNA stability. This project led to the discovery of a new mRNA decay mechanism, termed Staufen-mediated decay (Kim, Furic, DesGroseillers and Maquat, Cell 2005).

He later undertook his postdoctoral training in the laboratory of Dr Nahum Sonenberg at the Mcgill University, Goodman Cancer Centre, where he worked on the role of regulating mRNA translation in prostate cancer.

Dr Furic is a Research Fellow of The Terry Fox Foundation through an award from the National Cancer Institute of Canada. He holds a postdoctoral training fellowship from the DOD US Army-Prostate Cancer Research Program. Dr Furic's research interests include: eIF4E; translation initiation; PI3K; MAPK; tumour invasion.

Mr James Garland
Chief Executive Officer
Australian Prostate Cancer Research

James Garland has worked in the commercial and non-profit sectors, both in Australia and overseas.

For the past ten years, Mr Garland has been employed at senior management level within several non-profit organisations, with roles encompassing State Management, National Development, and Partnerships Management.

Recent organisations where he has served at senior levels include: Save the Children Australia, Able Australia Disability Services and, most recently, the Australian Prostate Cancer Research Centre Epworth.

Mr Garland holds a Bachelor of Commerce from Melbourne University, is an internationally Certified Fund Raising Executive (CFRE) and is currently completing an MBA.

Mr Eli Gibson
PhD Candidate
Robarts Research Institute
University of Western Ontario

Eli Gibson is a PhD Candidate at the Robarts Research Insitute, The University of Western Ontario. His research interests lie in the evaluation of imaging modalities via co-registration with histopathological reference standards.

Under the supervision of Dr Aaron Fenster and Dr Aaron Ward, his current research focuses on the evaluation of prostate cancer imaging modalities, including multi-parametric MRI and 18F fluorocholine PET.

Ms Lauren Giorgio
PhD Candidate
Basil Hetzel Institute for Translational Research
University of Adelaide

Ms Giorgio obtained her Bachelor of Health Science in 2008 and was awarded First Class Honours in 2009 in the Centre for Neurological Diseases, University of Adelaide.

In 2010, she worked as a research assistant in the Dame Roma Mitchell Cancer Research Laboratories before beginning a PhD in 2011 with Dr Grant Buchanan.

Her current research involves investigation of the anti-cancer mechanisms of curcumin, the active component of the Indian spice turmeric, in prostate cancer. Specifically, she is interested in the effect of curcumin on the whole prostate (including cells that surround the tumour), enhancing curcumin's efficacy in living systems (i.e. animals and eventually humans) and using curcumin to enhance the efficacy of other anti-cancer agents.

Dr Martin Gleave
Director
Vancouver Prostate Centre

Dr Martin Gleave is a Distinguished Professor and Vice Chair of the Department of Urologic Sciences at the University of British Columbia (UBC), Director of the Vancouver Prostate Centre, and a British Columbia Leadership Chair. He has published more than 340 papers with more than 14,000 citations, has an H-Index of 68, and has attracted more than $80M in research funding.

Dr Gleave's research characterizes molecular mechanisms mediating treatment resistance in cancer, focusing on stress-activated adaptive responses that drive acquired treatment resistance, and designing rational combination co-targeting strategies to create conditional lethality and improve cancer control.

He has patented several anti-cancer drugs and, in 2001, founded OncoGenex Pharmaceuticals to develop OGX-011, an inhibitor of the cell survival gene, clusterin, that potentiates anti-cancer therapies in many cancer models. OGX-427 is another agent targeting Hsp27 that has demonstrated single agent activity in Phase II studies of castrate resistant prostate cancer and bladder cancer.

Dr Gleave is the recipient of numerous awards, including the National Cancer Institute of Canada's prestigious William Rawls Award for contributions to cancer control in Canada; the Barringer Medal from the American Association of GU Surgeons; and the Eugene Fuller Award from the American Urological Association in 2013.

Assistant Professor Amir Goldkorn
Assistant Professor of Medicine
Norris Comprehensive Cancer Centre
Keck School of Medicine
University of Southern California

A/Prof Goldkorn's activities at the University of Southern California/Norris combine laboratory research and clinical practice, and specifically focus on developing the therapeutic and biomarker potential of circulating tumour cells (CTCs), cancer stem cells (CSCs), and telomerase.

In the field of CTCs, A/Prof Goldkorn and his associates have developed a novel slot microfilter for live CTC capture from patients' blood and have launched several clinical trials analyzing CTCs during treatment and at progression. In one of these (SWOG S0421, Phase III), they assayed telomerase as the first CTC-derived biomarker predictive of overall survival in this setting.

They have also developed and optimized techniques for isolation of ultra-pure CTCs (no white blood cell contamination) for whole transcriptome amplification and sequencing, and, in related work, developed a mouse CTC model to investigate mechanisms of cancer dissemination. In addition, they have launched a new multi-platform CTC Research Core at USC.

In the field of CSCs, A/Prof Goldkorn and his co-workers have demonstrated that cancer cells spontaneously convert in and out of a CSC-like, drug-resistant, highly tumorigenic state. They found that PI3K/AKT/β-catenin signalling plays a role in mediating this plasticity, and undertook epigenomic and ChIP-seq analyses to identify additional pathways involved in regenerating a CSC-like phenotype. In a related project, they discovered a new CSC-associated gene signature that predicts prostate cancer recurrence after prostatectomy.

They have also demonstrated that prostate CSCs have high telomerase levels and can be killed by reprogramming telomerase to add incorrect telomeric repeats, resulting in telomere uncapping and cell death. Subsequently, the team has designed and is testing a novel Telomerase Reprogramming Nanoparticle (TeRN), a systemically deliverable small molecule designed to specifically bind and reprogram telomerase.

Dr Jennifer Gunter
Postdoctoral Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Dr Gunter is an early career researcher at the Australian Prostate Cancer Research Centre-Queensland. She has a strong metabolic research background spanning almost 10 years. She completed her PhD at Oxford University examining the effect of obesity on beta cell function and type 2 diabetes, and has published peer reviewed articles and a book chapter on metabolic dysregulation related to obesity.

Dr Gunter has presented her findings at local and international conferences. She was awarded a University of Queensland Postdoctoral Fellowship in 2006 and returned to Australia to pursue studies into the turnover and metabolism of adipocytes in obesity. Dr Gunter was drawn to the area of prostate cancer research and the intersection between chronic metabolic disorders and their emerging relationship to cancer. Her strengths include expertise in the metabolic syndrome, insulin signalling and metabolism, and she has a demonstrated record of successful and productive research projects in metabolic research where she now applies her efforts to understanding the role of metabolic dysfunction in advanced prostate cancer.

Professor Vanessa Hayes
Professor and Head of Human Comparative Genomics
Garvan Institute of Medical Research

Vanessa Hayes is Professor of Human Comparative Genomics at the Garvan Institute of Medical Research / The Kinghorn Cancer Centre, and Professor of Genomic Medicine at the J. Craig Venter Institute in San Diego.

She holds Adjunct/Honorary Professorships at the University of New South Wales and University of Limpopo in South Africa, while being a member of the Reducing Cancer Disparities Program at the University of California San Diego Moores Cancer Centre.

Prof Hayes' work extends across the globe with a focus on defining the extent of human genome diversity and how this diversity impacts prostate cancer risk and disease outcomes.

Her interest in finding links to prostate cancer disparities globally led to her founding the Prostate Cancer Disparities Network (PCDN) in 2011, which includes researchers and studies from Australia, USA, and Africa. Her work has a particular focus on indigenous health, linking extreme phenotypes with genotypes, and gene-environment interactions. Her areas of expertise include human genomics, prostate cancer genetics, association studies, mitochondrial genomics, and population genetics.

Professor Adrian Herington
Associate Director IHBI (TRI)
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Following his PhD in Biochemistry at Monash University, Prof Herington spent two years as a postdoctoral fellow in the Laboratory of Dr William Daughaday, the "father of the insulin-like growth factors (IGF)". Returning to Australia in 1974, he worked primarily in the growth hormone (GH) and IGF fields at Prince Henry's Hospital Research Centre and the Royal Children's Hospital in Melbourne and developed a strong national/international reputation for contributions to understanding the characterisation, hormonal regulation, and solubilisation/purification of the GH receptor and the circulating soluble binding protein for GH.

His IGF research involved studies on the roles, nutritional and hormonal regulation, and clinical correlations of the IGF family, an endogenous IGF inhibitor, and the IGF binding proteins.

In 1995 he moved to the Queensland University of Technology (QUT) in Brisbane as Professor of Biochemistry (and, from 2000-2009, as Head of the School of Life Sciences).

He is currently the Associate Director of QUT's Institute of Health and Biomedical Innovation at the new Translational Research Institute (TRI) on the Princess Alexandra Hospital campus.

The recent focus of his research in the hormone-dependent cancer field, together with Dr Sally-Anne Stephenson, has been on the role and mechanisms of action of the Eph/Ephrin receptor tyrosine kinase-ligand system and their therapeutic implications in breast and prostate cancer.

Additional research interests involve the GH secretagogue, ghrelin, in hormone dependent cancers (prostate, breast and ovarian). Together with Assoc Prof Lisa Chopin, they have pioneered studies in the expression, characterisation and mechanism of action of ghrelin in stimulating cell proliferation in these cancer cells. Prof Herington has a total of 194 research papers/major reviews published in highly regarded refereed international journals/books and over 5,500 citations.

Dr Brett Hollier
Senior Research Fellow, Queensland Smart Futures Fund Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Dr Hollier is an early career researcher with an emerging national and international profile for his work in Insulin/Insulin-like growth factor (IGF) biology and mechanisms of cellular migration and cancer metastasis.

In recognition of his research, Dr Hollier has been invited and presented his work at both national and international conferences as well as external research institutes. Dr Hollier was recruited to the University of Texas M.D Anderson Cancer Center (MDACC) (Houston, TX, USA) in September 2008 to further his research interests into the mechanisms of cancer metastasis and was awarded a prestigious Susan G Komen for the Cure® Foundation Postdoctoral Fellowship (USA) (2009) for his research investigating the role of the epithelial-to-mesenchymal transition (EMT) in cancer stem cells and metastasis.

Dr Hollier returned to Australia (Sep 2010) to initiate his own independent research laboratory investigating mechanisms of cancer progression at the Institute of Health and Biomedical Innovation, QUT. Dr Hollier was recently awarded a three-year Smart Futures Fellowship from the Queensland Government with a focus on improving targeted therapies to halt cancer progression. To date, Dr Hollier has been directly involved in attracting $650K in competitive grant research funding including three Postdoctoral fellowships, one ARC Linkage, one Early Career Researcher and two Pilot Study grants.

He has published 13 peer reviewed articles, including nine original data journal articles, two invited journal review articles and two book chapters, in high impact internationally recognised journals. These have included PNAS, Oncogene, Stem Cells and two articles in Endocrinology with 205 citations to date. Reflecting Dr Hollier's research interests, these publications span the fields of growth factor biology and mechanism regulating cancer metastasis. Dr Hollier has been lead author on a number of papers describing for the first time the signalling and transcriptional mechanisms via which novel complexes of growth factors and matrix proteins induce cancer progression.

Dr Jeff Holst
Associate Faculty
Centenary Institute

Dr Holst completed his PhD in Immunology in 2003 at St Vincent's Hospital Centre for Immunology in Sydney, before undertaking postdoctoral studies at St Jude Children's Research Hospital in the USA.

He has a strong reputation for research excellence and implementation of new techniques, including mouse models, flow cytometry, and gene transfer. His most significant research contribution was published in Nature Immunology in 2008, and resulted in the receipt of the inaugural Research Australia Discovery Award.

After devising a ground-breaking new technique for expressing T-cell receptors in mice, he returned to Australia in 2006, to focus on cancer research with funding from the Cancer Institute NSW, the NHMRC, Cancer Council NSW, PCFA and the National Breast Cancer Foundation.

Dr Holst is currently Associate Faculty and Head of the Origins of Cancer Lab at the Centenary Institute, where his work is focussed on the role of nutrient transporters in prostate and breast cancer.

Dr Boris Holzapfel
PhD Candidate
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Dr Boris Holzapfel is an orthopaedic oncologist and surgeon with outstanding experience in the treatment of primary and secondary tumours of the musculoskeletal system. In this context he is trying to implement bone tissue engineering approaches into surgical therapy concepts of these tumours.

His translational research is focused on the biology of bone and soft tissue sarcomas and on the molecular mechanisms that lead to the development of bone metastases. By combining his knowledge about bone tissue engineering and tumour biology, he established several novel xenograft models of bone metastasis that make it possible to analyse the species-specific mechanisms of human cancer cell osteotropism.

Mrs Nina Holzapfel
PhD Candidate
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Nina Holzapfel completed her studies of Pharmacy at the Ludwigs-Maximilians-University (LMU), Munich, Germany. She is currently undertaking a PhD in Prof Hutmacher´s Regenerative Medicine group at the Institute of Health and Biomedical Innovation, Queensland University of Technology.

Her research interest focuses on drug testing in 3D culture models with a special emphasis on prostate, breast- and ovarian cancer. At present she is analysing the potential role of lycopene in the prevention and therapy of cancer.

Associate Professor Christopher Hovens
Scientific Director
Australian Prostate Cancer Research Centre Epworth
University of Melbourne

A/Prof Hovens is a co-founder of the drug discovery/development company, Velacor Therapeutics Pty Ltd for which he serves as Chief Scientific Officer. He is a co-inventor on 13 different patents in the area of drug discovery and development, ranging across indications from cancer to neurodegenerative disorders. The overall goal of the research program is to improve the accuracy of prognostic information for PCa patients by understanding the processes which govern the neovascularisation of prostate tumours at both the primary site, as well as at sites of distant metastasis.

By quantifying the levels of circulating pro-angiogenic/lymphangiogenic cells and bone marrow-derived progenitor cells in PCa patients, A/Prof Hovens's team will develop improved prognostic discriminators of the developmental course of the disease as well as surrogate biomarkers of treatment response.

By taking a concerted and comprehensive approach to the detection and quantification of circulating endothelial cells and their progenitors in PCa, A/Prof Hovens aims to fast-track the development of new clinical diagnostic and prognostic methodologies. These studies should definitively determine the role of mobilise-able endothelial progenitor cells in PCa neovascularisation and may improve our ability to clinically stratify PCa patients and predict their long-term response to existing and new developmental therapies.

Dr Elizabeth Hovey
Senior Staff Specialist
Prince of Wales Hospital

Dr Hovey is a Senior Staff Specialist in Medical Oncology at Prince of Wales Hospital, Conjoint Senior Lecturer at UNSW and Honorary Associate of the University of Sydney. Dr Hovey's main areas of expertise and research interest are genitor-urinary oncology and neuro-oncology.

Dr Hovey is also the Lead Principal Investigator (Study Chair) for an Investigator-initiated, industry sponsored, multicentre Phase III randomised clinical trial, addressing fatigue in the setting of prostate and breast cancer. This national 25-hospital study has completed recruitment and the results presented at GU ASCO ASM 2012 in San Francisco.

Dr Hovey has also been the local PI of numerous genito-urinary clinical trials at both Liverpool Hospital and Prince of Wales Hospital, particularly castrate-resistant prostate cancer. She is the outgoing Chair of the COSA (Clinical Oncological Society of Australia) Neuro-oncology Group after two elected terms (2006-2010); the current Deputy Chair of the NSW Cancer Institute Neurooncology Group (elected in for a second term), and the Secretary of COGNO (Cooperative Trials Group for Neuro-oncology) also serving on its Operations Executive.

She is the NSW Chief Investigator for the international EORTC/TROG Low Grade Glioma Study (Australian PI DR Gail Ryan), which is addressing the role of chemotherapy versus radiation in this very challenging setting. Dr Hovey is also collaborating with translational scientists on the anti-cancer effects of cholesterol trafficking and synthesis inhibitors as co-drugs in an *in vivo* glioblastoma multiforme model.

Professor Dietmar Hutmacher
Professor and Chair of Regenerative Medicine, Medical Device Domain Leader
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Professor Hutmacher's background includes a strong combination of academic and industrial experience. His expertise is in biomaterials, biomechanics, medical devices and tissue engineering. He is one of the few academics to take a holistic bone engineering concept to clinical application. More than 400 patients have been treated with the FDA-approved bone engineering scaffolds developed by Prof Hutmacher's Singapore-based interdisciplinary research group.

More recently, Professor Hutmacher has developed an international track record in adult stem cell research related to regenerative medicine. Regenerative medicine/tissue engineering is a rapidly growing multidisciplinary field involving the life, physical, and engineering sciences, and seeks to develop functional cell, tissue, and organ substitutes to repair, replace or enhance biological function that has been lost due to congenital abnormalities, injury, disease or aging. It includes both the regeneration of tissues *in vitro* for subsequent implantation in vivo, as well as regeneration directly *in vivo*.

In addition to having a therapeutic application, tissue engineering can have a diagnostic application, where the engineered tissue is used as a biosensor. Engineered tissues can also be used for the development of drugs, including screening for novel drug candidates, identifying novel genes as drug targets, and testing for drug metabolism, uptake, and toxicity.

Dr Varinder Jeet
Postdoctoral Fellow
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Dr Varinder Jeet received a Masters degree in Biotechnology from Punjabi University, India and went on to complete his PhD studies at the University of New South Wales, Sydney, Australia, in 2009.

He started his PhD in 2005, after receiving the Sydney Foundation of Medical Research Postgraduate Scholarship. During his PhD, he investigated various aspects of prostate cancer (PCa), including development of a suitable model for prostate cancer progression, study of mechanisms underlying advanced PCa and targeted gene therapy mediated approaches to curb the growth and proliferation of PCa cells.

Soon after completing his PhD, he moved to Brisbane to work on the dendritic cell-based cancer immunotherapy at the Mater Hospital.

Dr Jeet's research interests include: the identification of the molecular changes associated with the progression of prostate cancer towards androgen independence via use of high-throughput bioprofiling for screening, validation, and functional evaluation of targets.

His current project at The Australian Prostate Cancer Research Centre-Queensland involves the identification and targeting of various molecular markers that underlie the progression of prostate cancer towards androgen independence.

Dr Bill Jordan
Director
Centre for Biodiscovery
Victoria University of Wellington

Dr Jordan graduated with a PhD in Biochemistry from Victoria University of Wellington. He has carried out research in the University of London; Department of Clinical Pharmacology, Royal Postgraduate Medical School, Hammersmith, London; the Clinical Research Unit of the Walter and Eliza Hall Institute of Medical Research in Melbourne; and the Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio.

Dr Jordan is a Director of the Human Proteome Organization (www.hupo.org), a Vice-President and Council Member of the Asia Oceania Human Proteome Organisation (www.aohupo.org), and a participant in the Human Proteome Project.

His research uses quantitative proteomics for biological discovery and for applications to human health and medicine and, collaboratively, numerous applications to animal, plant, and microbial biotechnology.

His current major proteomics research includes: analysis of proteins that can be used to predict the presence and course of prostate cancers, molecular characterisation of the cellular effects and targets of biologically active molecules including drugs and biotoxins, and technologies for characterisation of membrane proteins.

Dr Anthony Joshua
Clinician Scientist
Princess Margaret Cancer Centre

Dr Anthony Joshua completed his medical oncology training at the Royal Prince Alfred hospital in Sydney, Australia before moving to Toronto to complete a PhD under the supervision of Dr Jeremy Squire in prostatic carcinogenesis.

He has since joined the Department of Medical Oncology at Princess Margaret Hospital, specialising in genito-urinary malignancy and melanoma.

Dr Joshua is currently an Assistant Professor with the University of Toronto and a clinician-scientist at the University Health Network.

His research interests include the unfolded protein response (working with Dr Brad Wouters), autophagy in prostate cancer, mechanisms of enzalutamide resistance, prostate cancer immunotherapy and translational research in GU and melanoma trials and clinical trial design.

Dr Lidija Jovanovic
Postdoctoral Fellow
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Dr Jovanovic is a molecular scientist who obtained her degrees from the University of Belgrade, Yugoslavia and the University of Otago, New Zealand.

She completed her PhD investigating clonal origins and molecular phenotypes in multiple and histologically diverse tumours in multifocal papillary thyroid carcinoma.

Dr Jovanovic's postdoctoral research focused on markers of progression in prostate cancer and molecular characterization of synchronous clear cell/papillary renal carcinomas.

She joined the Australian Prostate Cancer Research Centre - Queensland in March 2009, where her areas of research include stage-specific differentiation markers within a prostate stem-cell unit and molecular pathology of prostate carcinoma.

Dr John Lai
Postdoctoral Fellow
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Dr Lai's research interests are centred on both the molecular events that lead to, or are the result of cancer progression. He has spent approximately nine years working in the field of advanced prostate cancer (CaP) genetics, focusing on androgen receptor (AR) pathways/targets in this disease.

During this time, Dr Lai studied dysregulated molecular events that are important in CaP such as androgen-induced gene expression profiling in CaP cells, and aberrant AR interactions with DNA mediated by SNPs at CaP risk loci (GWAS).

He is particularly interested in the data emerging from next generation genome-wide sequencing platforms, which are shaping understanding of how genes are regulated and transcribed.

Dr Lai's current research focuses on the role of hormones in regulating transcription of novel RNA (antisense RNA, intergenic RNA, alternative transcripts, chimeric transcripts), and the role of these prostate-specific RNA in normal and malignant prostate development.

Dr Jacques Lapointe
Associate Professor
McGill University

Dr Lapointe obtained his MD and PhD degrees from Université Laval in Québec, Canada followed by a postdoctoral training in gene expression and DNA copy number alterations profiling at Stanford University in California, USA. Dr Lapointe is currently an Associate Professor in the Department of Surgery, Division of Urology at McGill University.

The main focus of Dr Lapointe's laboratory is prostate cancer genomics to better understand cancer biology and develop prognostic biomarkers – specifically to study gene expression and DNA copy number alteration profiles of prostate cancer using DNA microarray technology.

Their goals are to increase understanding of prostate cancer pathology, establish a new molecular classification of prostate tumours, and identify new prognostic and diagnostic markers.

Dr Mitchell Lawrence
Postdoctoral Fellow
Prostate Cancer Research Program
Monash University

Dr Lawrence completed his PhD with Prof Judith Clements at the Australian Prostate Cancer Research Centre-Queensland, Queensland University of Technology.

In 2010, he joined Monash University to work with Dr Caroline Gargett and Prof Gail Risbridger. Dr Lawrence is funded by an NHMRC Early Career Fellowship and a Movember Young Investigator Grant awarded through Prostate Cancer Foundation of Australia's Research Program.

The focus of Dr Lawrence's research is the tumour microenvironment - in particular, defining the differences between normal prostate fibroblasts and cancer-associated fibroblasts. These studies involve flow cytometry of fresh patient specimens and primary cell culture.

Dr Melanie Lehman
Postdoctoral Fellow
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Melanie Lehman received a BSc from the University of Alberta (cell biotechnology), a certificate in software engineering from Carleton University, a PhD from the University of British Columbia (computational biology and prostate cancer) and currently holds a joint position as a postdoctoral research fellow at the Vancouver Prostate Centre and Australian Prostate Cancer Research Centre-Queensland.

She has worked for the past 10 years in prostate cancer research utilizing computational approaches to analyse genome-wide profiling data from cell lines, animal models, and human tissue samples.

Dr Lehman has integrated data from high density microarrays and next-generation sequencing (RNA, small RNA, ChIP, and DNA) technologies to study the regulation and interplay of protein-coding and non-coding RNAs in steroid response and treatment resistance.

Miss Claire Levrier
PhD Candidate
Eskitis Institute
Griffith University

Miss Levrier completed her Master in Natural Product Chemistry at the University of Strasbourg, France in 2011. She then took up a research position at the ICSN/CNRS Gif-sur-Yvette, France, under the supervision of Dr Marc Litaudon and Dr Françoise Guéritte. 'Phytochemical and biological studies (glioblastoma) of *Antiaris toxicaria* and *Solmsia calophylla*',

In 2012, Miss Levrier was a visiting scientist at the Eskitis Institute for Drug Discovery, Griffith University, Brisbane, under the supervision of Dr Rohan Davis, where she worked on a project entitled: "Antimalarial alkaloids from the Australian endemic plant *Goniothalamus australis*".

This year she took up a PhD candidature at the Eskitis Institute for Drug Discovery, Griffith University, Brisbane, under the supervision of Dr Rohan Davis, Dr Martin Sadowski and Professor Colleen Nelson . Her current research project is: "New cytotoxic (prostate cancer) compounds from Australian endemic rainforest plants."



Dr John Lewis
Frank and Carla Sojonky Chair in Prostate Cancer Research
University of Alberta

Dr Lewis's research program utilizes intravital imaging of the tumour microenvironment to functionally elucidate the "switches" of tumorigenesis, namely tumour neoangiogenesis and the acquisition of tumour cell motility.

He is investigating novel nanoparticles that are being developed for the early detection of prostate cancer, drug delivery, and the *in vivo* study of tumour cell invasion and metastasis.

These intimately related projects are facilitated by an integrated research platform for long term time-lapse intravital imaging of human cancer progression.

Dr Lewis holds a PhD in biochemistry from the University of Victoria, BC, and did his postdoctoral training at The Scripps Research Institute in La Jolla, California.



Professor Paul Li
Professor, Chemistry
Simon Fraser University

Dr Paul Li obtained his Ph.D in the University of Toronto in 1995. Then he developed the microfluidic lab-on-a-chip at the University of Alberta and City University of Hong Kong.

Dr Li joined Simon Fraser University in 1999, and became full professor in 2010. Dr Li conducted microfluidic single-cell analysis for analyzing the effects of chemical compounds on individual cancer cells. He has also developed the nanobioarray chip to detect single base-pair cancer gene mutation.

Dr Li has published a monograph: Fundamentals of lab on a chip for biological analysis and discovery. He is associate editor of the international journal called "Canadian Journal of Pure and Applied Sciences". Dr Li is the inventor of 4 granted patents and 5 pending patents, and he is the founder of ZellChip Technologies Inc. specializing in microfluidic-based instrument for cellular and DNA analysis.

Ms Michelle Liberio
PhD Candidate
Eskitis Institute
Griffith University

In 2006, after receiving her Diploma in Biology from the University of Brasilia (Brazil), Ms Liberio received her Master's degree in Animal Biology at the same university. She studied peptides isolated from the skin secretions of frogs, identifying antimicrobial and cytotoxic molecules. In the same year, she decided to acquire new skills in New Zealand, studying visual communication for three months.

Ms Liberio arrived in Australia in 2009 to undertake her PhD studies at Griffith University's Eskitis Institute for Cell and Molecular Therapies investigating natural products isolated from Australian ascidians. Her PhD project aims to purify compounds that are cytotoxic to prostate and breast cancer cells and to identify some of the targets of these secondary metabolites.

Dr Patrick Ling
Senior Research Fellow
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute
Honorary Assistant Professor, University of Hong Kong

Dr Ling graduated with a Bachelor degree in the Department of Biochemistry at The Hong Kong University of Science and Technology. He obtained his MPhil and PhD degrees in The University of Hong Kong.

In 2005, he received the Outstanding Research Postgraduate Award. He was a Postdoctoral research fellow in the Department of Anatomy at The University of Hong Kong and was promoted to Research Assistant Professor in the same department. He is currently a senior research fellow in the Institute of Health and Biomedical Science and the Australian Prostate Cancer Research Centre—Queensland.

He studies the molecular mechanisms that underlie prostate cancer development. He is also interested in investigating the application of fundamental research to the development of improved treatments for hormone-refractory prostate cancer.

Dr Amy Lubik
Postdoctoral Fellow
Vancouver Prostate Centre

Dr Lubik studied biochemistry / molecular biology at Simon Fraser University in British Columbia, Canada, finishing in 2006 with Honours in HIV research, and a co-operative education certificate, having worked multiple semesters at the Vancouver Prostate Centre, and Merck Frosst Paramedical in Quebec, Canada. While attending University, she was heavily involved in the Red Cross Club, Doctors without Borders, and was president of the swing-dancing club.

Following her honours project, she travelled to Ternopol, Ukraine, to teach HIV education in high schools and Universities. She then returned to Vancouver to work at the Prostate Centre, specifically on steroidogenesis and lipogenesis.

Dr Lubik completed her PhD in 2011 at Queensland University of Technology, Brisbane, Australia. During her PhD, she chaired the QUT Movement for Universities Allied for Essential Medicines, and had an internship in neglected disease patent law with Cambia at QUT. Her thesis focused on insulin and IGF2 and their effects on prostate cancer progression. Her work has largely been interwoven with the Vancouver Prostate Centre and the Australian-Canadian Prostate Cancer Research Alliance. This work has resulted in a seminal publication on insulin effects on steroidogenesis and four other manuscripts under revision.

Dr Lubik continues to be interested in metabolism and prostate cancer; however, her current work focuses on a) the epithelial-stromal interactions that contribute to steroidogenesis to further prostate cancer and drug resistance; b) prostate cancer stem cell contributions to disease.

Dr Geoff Macintyre
Postdoctoral Researcher
National ICT Australia (NICTA)
University of Melbourne

Dr Macintyre is interested in developing computational techniques to interpret integrated genomics data derived from lethal prostate cancer samples. In particular, his focus is on identifying how aberrant modes of gene regulation affect disease phenotypes.

Dr Macintyre's current research involves the integration of heterogeneous genomic data (CNVs, SNPs, RNA, Histone marks, DNA methylation, TF ChIP-SEQ) to help understand the molecular mechanisms underlying prostate cancer, as well as biomarker discovery for improved diagnosis and prognosis prediction in prostate cancer. He employs ENCODE data to support molecular analyses and is exploring the interpretation of the impact of epistatic interactions.

Dr Rose Martiniello-Wilks
Senior Lecturer and Head
Translational Cancer Research Group (TCRG)
School of Medical and Molecular Biosciences
University of Technology Sydney

Dr Martiniello-Wilks is a Senior Lecturer and Head of the Translational Cancer Research Group in the Dept of Medical and Molecular Biosciences, Faculty of Science, University of Technology Sydney (UTS). Her prostate cancer (PCa) research experience began in Prof Pamela Russell's Oncology Research Centre, Prince of Wales Hospital NSW, UNSW. This research was performed in collaboration with CSIRO Molecular Science.

Over the past 13 years Dr Martiniello-Wilks has been developing novel cell and gene therapies to eliminate advanced PCa. To achieve this goal, she and her collaborators have raised over $3.5 million in research and research infrastructure funding from the Prostate Cancer Foundation of Australia, Sydney Cancer Centre Foundation, Cancer Institute NSW, Department of Defense U.S. Army Prostate Cancer Research Program, and the National Cancer Institute USA.

Dr Martiniello-Wilks has been a named inventor on three provisional patents and one international patent, and has published over 70 peer reviewed publications. Highlights include a 'Gene Medicine for Prostate Cancer: FP23' clinical trial (NCT00625430; http://www.ClinicalTrials.gov) supported by international patent PCTAU03/00381 to be conducted at the Prostate Cancer Centre, St Vincent's Hospital, Sydney in 2010. This work received a Platinum Nomination for the CSIRO Chairman's Medal in 2008. Aspects of this work have been presented internationally at the AACR, Association of American Pharmaceutical Scientists, the European, American and British Gene Therapy Society Conferences.

Dr Martiniello-Wilks was convenor of the Sydney Cancer Centre (Lifehouse at RPAH) Research Meetings (2005-8) that reported on the excellent cancer research conducted on the RPAH/University of Sydney campus, nationally and internationally to the public, students, researchers, and medical professionals. She has been an elected Australasian Gene Therapy Society (AGTS) Executive Committee member since 2005 and currently serves as Vice-President.

Dr Stephen McPherson
Postdoctoral Fellow
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

In 1997, Dr McPherson completed a Masters Degree investigating the role of TGF-β related growth factors in prostate cancer from Monash University.

He went on to receive his PhD from Monash University in 2003 and subsequently took up a position at the Monash Institute of Medical Research at Monash University, where he investigated the role of hormonal regulation in controlling the development of benign and malignant prostate disease. This led him to the study of the roles of steroid hormone receptors, particularly estrogen receptors, in prostate development and disease.

Dr McPherson joined the APCRC–Q to study the relationship of AR with progesterone in the development of castrate resistance in prostate cancer and the roles of other nuclear hormone receptors in prostate cancer. His research interests include: changing expression of nuclear hormone receptors in prostate disease, prostatic response to the changing hormonal environment, aging, progression of prostate cancer, and the role of ERβ in prostate growth and disease.

Mrs Erica Mohr
Senior Physiotherapist
Continence Advisory Services
Queensland Health

Erica Mohr is presently researching the clinical outcomes for clients post prostatectomy who have received multidisciplinary education program prior to their prostatectomy. A two year longitudinal study using the SF36 and EPIC tools to review clients post open prostatectomy.

Ms Erica Mohr's research interests lie in the areas of cancer control, education, patient care, and cancer survivorship.

In the course of her work she collaborates with researchers from the University of Queensland, and the Urology Department at Nambour General Hospital.

Dr Lorelei Mucci
Associate Professor
Harvard School of Public Health

Dr Mucci is a cancer epidemiologist with more than ten years of research and teaching experience. She is an Associate Professor of Epidemiology at the Harvard School of Public Health and lead the Cancer Epidemiology program at the Dana Farber/Harvard Cancer Center (DF/HCC).

Her research has focused on biomarker studies investigating the etiology of cancer risk as well as studying lifestyle and molecular factors associated with cancer progression. Over the past eight years, her research focus has turned to prostate cancer tumour biomarkers.

Dr Mucci is Principal Investigator of several funded grants across various aspects of prostate cancer etiology, molecular subclassification and prognostication. She led the tumour biorepositories of 3,000 prostate cancer patients who are participants in the Physicians' Health Study and the Health Professionals Follow-up Study. Moreover, she is co-leader of a multi-disciplinary, international prostate cancer patho-epidemiology collaboration of researchers at Harvard as well as medical institutions in Sweden, Iceland, Ireland and Italy.

Dr Mucci's research includes studies focused on immunohistochemistry and large-scale genome wide expression profiling study within large cohorts of men with prostate cancer. Teaching and mentoring has been a core component of her academic work. She has mentored of 25 graduate students, post-doctoral fellows and clinical fellows, and served as co-Director of a peer-mentoring program of 40 fellows and instructors.

Dr Eleanor Need
The Hospital Research Foundation Early Career Research Fellow
Basil Hetzel Institute for Translational Research
University of Adelaide

Dr Need's research interests are focused on the role of androgens and the androgen receptor in different cell types in men. Her interest in steroid signalling began 10 years ago, where she investigated the evolutionary relationships of the steroid receptors and was instrumental in discovering the last common ancestor to all of the steroid receptors was estrogen receptor-like.

Since completing her PhD, Dr Need has investigated the ability of utilizing AR activity as a means of measuring the biologically active portion of androgens in the serum of 1,200 men and the important role of a region in the amino terminus of the androgen receptor, which is a mutation hot spot for somatic mutations in prostate cancer and governs intra-molecular interactions, coregulator interactions, DNA binding and ability of the receptor to transactivate genes in prostate cancer cells.

More recently, she has begun focusing on the importance of androgen receptor action and crosstalk with growth factors in the prostate stromal microenvironment.

Professor Colleen Nelson
Executive Director
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Prof Nelson is the founding Executive Director of the Australian Prostate Cancer Research Centre - Queensland, and Chair of Prostate Cancer Research at Queensland University of Technology. She is also Director of the Australian-Canadian Prostate Cancer Research Alliance.

Prior to her appointment in Australia, she was a founding scientist of The Prostate Centre in Vancouver. Since arriving in Australia in 2007, Prof Nelson has been awarded >$13 million in research grants. In 2009, she was awarded the prestigious Queensland Smart State Premier's Fellowship.

Prof Nelson's expertise is in translational prostate cancer research, specifically in identification of potential therapeutic targets, their *in vitro* and *in vivo* validation, validation through molecular pathology approaches, and their translation into potential clinical application.

These outcomes are derived from her expertise in high-throughput applications in gene (protein coding and non-coding) and tissue expression profiling, gene regulation, next gen sequencing applications, and bioinformatics. She is particularly interested in characterizing responses to androgen deprivation therapy and progression to castrate resistance and endocrine action of steroid hormones and insulin and insulin-related hormones.

Mr Kenneth Ng
Graduate Student
University of Toronto

Kenneth Ng is interested in developing technologies to assist in the focal treatment of localized prostate cancer. His focus is in applying discoveries in nanotechnology to complement existing therapeutic and diagnostic approaches in prostate cancer. Recently Mr Ng and his co-workers have been working on developing photoacoustically-active functional nanomaterials. One of the biggest achievements in their lab was the synthesis of the first all-organic nanoparticle with photoacoustic, photothermal and photosensitizing properties.

Mr Ng's project involves examining strategies for real time monitoring of treatment progression during focal thermal therapy of localized prostate cancer. Specifically, he has designed a nanoparticle that can provide imaging contrast by photoacoustic imaging and has a tunable phase transition, which enables sensitive temperature sensing properties upon injection. The next step is to examine the effectiveness of using photoacoustic imaging in conjunction with this nanoparticle to monitor tumour temperature during focal thermal therapy in both xenograft and orthotopic models of prostate cancer.



Dr Christopher Ong
Senior Scientist
Vancouver Prostate Centre

Dr Ong's specific research interest revolves around studying disease mechanisms at the molecular and cellular levels. A strong underlying basis of his research efforts is in translational research with the aim of translating laboratory-based discoveries into new therapeutics. In particular, Dr Ong's research interests are primarily focused on understanding the signal transduction pathways that control a variety of cellular responses. He believes that insights into these pathways will guide the development of new molecular targeted therapies for treating a variety of diseases including cancer and immune related disorders.

The primary focus of Dr Ong's research program is to understand the molecular mechanisms that govern the progression of prostate cancer from a state of androgen sensitivity to hormone independence with the hope of developing novel therapeutic strategies to prevent or delay the progression of prostate cancer to androgen independence. His primary focus has been on the PTEN tumour suppressor gene, which is among the most frequently mutated genes in cancer. One or both copies of PTEN is mutated in over 70% of primary prostate cancer cases and PTEN is completely inactivated in over 50% of advanced prostate cancer cases, which correlates with a poor prognosis.

Dr Ong's laboratory is currently studying how mutations of that gene confer protection of prostate cancer cells from cell death and resistance to chemotherapy, as well as how loss of PTEN influences the progression of prostate cancer cells to androgen independence. Based on observations to date, Dr Ong is testing the potential utility of several classes of small molecule drugs that act to down-modulate the PI3K survival pathway and other growth and survival pathways in the treatment of prostate cancer. These novel compounds have tremendous promise as lead compounds for development of therapeutics that target a primary defect associated with prostate cancer and other malignancies. Dr Ong's laboratory is also involved in the development of unique prostate tumour model systems, which are used to characterize the function of a number of genes in normal and malignant prostate biology.

Professor Klaus Pantel
Professor and Director Department of Tumour Biology
University Medical Center Hamburg-Eppendorf

Prof Dr Klaus Pantel is Professor of Medicine and Director of the Department of Tumour Biology at the University Medical Centre Hamburg-Eppendorf (UKE). He also served as Deputy Director of the Centre of Experimental Medicine, and as Professor of Molecular Genetics and Head of the Molecular Oncology in the Department of Gynaecology and Obstetrics at the UKE.

Prior to joining the UKE he held appointments as Associate Professor, as Research Scientist and Head of the Micrometastasis Research Laboratory and as Scientific Head of the Animal Care Unit at the Institute for Immunology at the Ludwig Maximilians University of Munich. He also served as Head of the Project Group Early Metastasis of Epithelial Tumours at the Tumour Centre Munich.

His research focuses mainly on CTC/DTC detection and characterization (CTCs: circulating tumour cells/DTCs: disseminated tumour cells). He is also interested in the epigenetic regulation of tumorigenesis and stem cell differentiation and in the identification and the structural and functional characterization of tumour-associated genes. Further topics of his research are tumour-stroma interactions, circulating cell-free nucleic acids, tumour immunology and the identification and functional characterization of metastasis-associated genes.

Prof Pantel is co-founder of the Micromet GmbH in Martinsried (since 1994) and was coordinator of the Oncology Research Program at the UKE from 2002 to 2008. He is member of the editorial boards of various scientific journals and also serves as reviewer for numerous funding agencies (including Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe) and scientific journals. Among other professional memberships Prof Pantel is member of the German Cancer Society and the American Association for Cancer Research. Furthermore he is recipient of various awards (including the German Cancer Award 2010 and the AIO Medical Oncology Award 2008)



Dr Robert Paproski
Postdoctoral Fellow
University of Alberta

Dr Robert Paproski received his B.Sc. (pharmacology) and PhD (oncology) at the University of Alberta. He is currently supervised by Dr Roger Zemp and Dr John Lewis and works on a variety of projects including developing new uses for ultrasound in oncology.

Dr Paproski's main research interests include using ultrasound to induce pore formation in cancer cell membranes (sonoporation) which can liberate biomarkers (proteins/RNA) as well as allow cytoplasmic entry of therapeutics.

He is also developing specialized perfluorocarbon-based ultrasound contrast agents (called nanodroplets) which are smaller than currently used microbubbles. These smaller nanodroplets have the ability to accumulate in tumours due to the enhanced permeability and retention effect, potentially allowing enhanced detection of tumours with ultrasound.

Professor Stephen Pennington
Professor of Proteomics
University College Dublin

Prof Pennington graduated from Imperial College of Science and Technology (University of London) with a joint honours degree in Chemistry and Biochemistry before completing a PhD in Biochemistry at the University of Cambridge.

During his PhD he was awarded an Elmore Medical Research Fellowship. It was during this fellowship that his interests in the regulation of the mammalian cell cycle began. The subject of his research that was continued when he moved the Department of Human Anatomy and Cell Biology at the University of Liverpool to take up a post as a Wellcome Trust funded lecturer.

While working as a Lecturer and later as a Senior Lecturer, his research included the use of two-dimensional gel electrophoresis (2-DE), which was subsequently combined with mass spectrometry for protein characterisation.

Prof Pennington has been active in the practical implementation of collaborative proteomics projects and set up a multi-user proteomics facility at the University of Liverpool that served as a 'prototype' for the facility he established when he moved to the Conway Institute in 2003. His vision for the development of proteomics in UCD has been to use his expertise and experience to apply proteomics (in its broadest definition) to a diverse range of research programmes. Of particular interest are the development of translational clinical translational projects that align research results to the clinical setting and the development of methods for the discovery and subsequent quantitative measurement of proteomic biomarkers.

Prof Pennington received a Sir Henry Wellcome Commemorative Award for Innovative Research, and has been Director of Research and member of the Board of a Cambridge-based seed-corn funded fledgling biotech company. He has served in small scale consultancy capacities for a number of commercial organizations, and has given many presentations in the UK, Europe, the US and Asia, including two industry funded lecture tours of Asia, where he gave presentations in Taiwan, South Korea, Hong Kong, and mainland China.

He is on the editorial board of several journals, including in a more senior capacity for 'Proteomics' and the 'Journal of Proteomics' and regularly reviews manuscripts and grants for a number of international organisations.

Dr Ngoc Pham
Research Fellow
Eskitis Institute
Griffith University

Dr Ngoc Pham's expertise is in natural product isolation, drug design, and synthesis. She is particularly interested in identifying natural products, which act synthetic lethal with non-oncogenes involving in castrate-resistant prostate cancer.

Dr Lisa Philp
Postdoctoral Research Fellow
Adelaide Prostate Cancer Research Centre
University of Adelaide

Dr Philp undertook studies for a Bachelor of Science (Biomedical Science) majoring in physiology and pharmacology, and a Bachelor of Science (Honours) at the University of Adelaide. She subsequently completed her PhD in Medicine at the University of Adelaide investigating the effect of diet and gender on obesity, body composition, and metabolism, under the supervision of Prof Gary Wittert, a leading endocrinologist and researcher with interests in obesity and men's health.

Due to her strong interest in developing expertise in another critical aspect of men's health, namely, prostate cancer, Dr Philp now works as a postdoctoral fellow with A/Prof Lisa Butler, Prof Wayne Tilley and Dr Tanya Day, at the Adelaide Prostate Cancer Research Centre.

Dr Philp's key research interest is in investigating factors that may influence prostate cancer initiation and progression and, as a result, she was involved with a team of researchers that generated a novel Gleason progression cohort and a series of tissue microarrays with the aim of studying prostate cancer progression.

In addition, Dr Philp has made a considerable contribution to the implementation and customisation of a new computerised image analysis system at the Adelaide Prostate Cancer Research Centre. She is also a chief researcher involved in characterising a novel mouse model of altered androgen action.

Dr Ruth Pidsley
Postdoctoral Researcher
Garvan Institute of Medical Research

Dr Pidsley is a postdoctoral researcher in the Cancer Epigenetics group at the Garvan Medical Research Institute, NSW. She is working on a Cancer Australia grant to investigate epigenetic variation in human prostate cancer stromal cells.

Dr Pidsley graduated from Oxford University in 2006 with a degree in Human Sciences. She then spent two years working as a research assistant in a Psychiatric Genetics laboratory at the Wellcome Trust Centre for Human Genetics, Oxford, UK.

She joined the Institute of Psychiatry at King's College London, UK in 2008, and was awarded an MSc in "Social, Genetic and Developmental Psychiatry" in 2009, and a PhD in 2013 for her thesis titled: "Profilling DNA methylation in the human brain and neuropsychiatric diseases".

Dr Pidsley recently moved to Australia to take up a postdoctoral position, which will allow her to apply the skills developed during her PhD to the study of molecular changes in the tumour microenvironment in prostate cancer.

Dr Des Pink
Research Associate
University of Alberta

Dr Pink is a Research Associate with Dr John Lewis (University of Alberta). His main work areas include (1) preclinical development of novel biomarkers for prostate cancer screening and diagnosis, (2) small molecule library screening for various cancer therapeutic applications and (3) preclinical development of a liposomal / nanoparticle drug delivery platform.

His main focus is the development of prostate cancer microparticle biomarkers. Together with his co-workers, Dr Pink has identified new markers which are used in a "liquid biopsy" to detect and enumerate microparticles and which are not only prostate cancer specific, but also indicative of disease status (e.g. normal, benign or metastatic).

The team is currently working on both retrospective and prospective sample analyses to further validate this assay but also and in collaboration with others, to identify and develop new prostate cancer specific biomarkers using proteomics, metabolomics and genetics.

While Dr Pink's main area of interest is the development of a liquid biopsy for prostate cancer microparticle biomarkers, his broad interest lies with assay and platform development for preclinical applications. The Lewis lab utilizes many standard assay protocols, but it is best known for the development and use of the ex ovo chicken embryo model, also known as the chorioallantoic membrane or CAM model. This model system is used for investigating angiogenesis, metastasis, tumour biology, tumour vascular permeability, and nanoparticle, imaging agent and drug delivery. The system has permitted the team to investigate and develop many imaging agents, biomarkers, antibodies, small molecule drugs with real time, and quantitative analyses under *in vivo* conditions. Much of Dr Pink's previous work was spent developing a real time, intravital tumour vascular permeability assay in the CAM model system.

Richard Rebello
PhD candidate
Prostate Cancer Research Program
Monash University

Mr Rebello is a PhD candidate in the Risbridger group at Monash University where he is investigating potential selective inhibitors as therapies for oncogene driven cancers with a particular focus on cell signalling and disease.

His current research interest lies in the influence of the various cell growth/division and death pathways in prostate cancer, especially those driven by the MYC oncogene.

Dr Paul Rennie
Director of Laboratory Research, Vancouver Prostate Centre
Professor, Urologic Sciences, University of British Columbia

Dr Rennie is the co-founder and Director of Laboratory Research for The Vancouver Prostate Centre. His lab has had a long history of characterizing hormone regulation of prostate cancers and has contributed much of the groundwork for the development of widely used, cost-efficient treatments for advanced prostate cancer in the eighties and for providing the mechanistic basis for intermittent androgen suppression treatment protocols.

Dr Rennie's current research is aimed at determining how androgens regulate gene transcription and how to use this knowledge to prevent progression to castration resistance/androgen independence in prostate cancers. In this regard, he is using RNA interference and a small molecule approach to knockdown, and to inhibit, the androgen receptor. In addition, he is working to develop replication-competent oncolytic viruses that can selectively target and kill prostate tumour cells.

As Director of Laboratory Research for The Prostate Centre, and as PI of the Terry Fox/NCIC Program Grant on Prostate Cancer Progression, Dr Rennie has established an integrated, multidisciplinary group to study molecular, cellular and translational aspects of prostate cancer progression to androgen independence. The program grant, which was initially awarded in 1998, is ongoing and has been repeatedly renewed, yielding over $15million in research funds. This program has provided the central thematic basis for much of the research currently performed at The Vancouver Prostate Centre and has established core facilities which are the nucleus of gene array, pathology and animal model activities.

In recognition of his career achievements in science, Dr Rennie was named a Fellow of the Canadian Academy of Health Sciences in 2007.

Professor Gail Risbridger
Head, Prostate Cancer Research Group
Deputy Dean-Strategic Projects, Faculty of Medicine, Nursing and Health Sciences
Research Director, Monash Comprehensive Cancer Consortium
Monash University

Professor Gail Risbridger is an NHMRC Research Fellow and a career academic and researcher with > 20 years experience in Prostate Cancer research and Men's Health. A graduate of Monash University, she worked in the Departments of Anatomy and in Physiology before becoming a founding member of the Monash Institute of Medical Research (MIMR). She returned to campus in 2009 as Deputy Dean Strategic Projects, to lead the developments of Monash Comprehensive Cancer Consortium (MCCC) and Monash Partners Academic Health Science Centre. She is the Research Director of MCCC and Chair, Faculty Research Centres and Institutes Committee.

As head of an internationally recognised research team of scientists and clinicians working on prostate cancer and andrology-related projects within the Department of Anatomy and Developmental Biology at Monash University, Prof Risbridger is one of Australia's leading prostate cancer researchers, with particular interest in the biology of stromal-epithelial cell interactions in normal and tumour tissue using tissue recombination, animal and human specimens. She pioneered the use of stem cells for recombination studies combining stem cell biology with endocrinology.

She has >190 publications, including original articles in general biomedical journals and in specialist journals of Endocrinology, Cell Biology, Urology, Pathology, Oncology and Environmental Sciences including publications in Nature Methods, Nature Cancer Reviews, PNAS, FASEB and Am J Pathology and has received substantive National and International grant funding related to prostate cancer.

Her academic and industry collaborations have built infrastructure and trained some of the workforce required to underpin the national research effort in Australian Prostate Cancer Research, including a National tissue bank with Victorian State Government informatics support. She has advisory roles in Andrology Australia and the Freemasons Foundation Centre for Men's Health. Her awards include an International Fulbright Senior Scholar Award, British Endocrine Society Asia-Oceania Medal and Honorary Life Member of Endocrine Society of Australia.

Dr David Rivest-Henault
Postdoctoral Fellow
Australian e-Health Research Centre
Commonwealth Scientific and Industrial Research Organisation (CSIRO)

Dr Rivest-Hénault received his B.Eng. with highest honours in automation engineering from University of Quebec's École de technologie supérieure, Montreal, in 2005.

He then joined the Synchromedia Laboratory for multimedia communication in telepresence with scholarships from both NSERC and FQRNT, and received his Ph.D. with highest honours in 2012.

He was a visiting researcher at Siemens Corporate Research, Princeton, NJ, in 2010, and a software expert in a computer vision startup, C-Tec, Laval, Québec (2004-2010).

Dr Rivest-Hénault is now a Postdoctoral Fellow at CSIRO, The Australian e-Health Research Centre, Royal Brisbane and Women's Hospital, where he is working on imaging methods for MR-based planning and adaptive prostate radiation therapy.

Professor Pamela Russell
Head of Biomedical Imaging and Prostate Cancer Models
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Prof Pamela Russell joined the Australian Prostate Cancer Research Centre–Queensland in 2009. Her laboratory has earned an international reputation for its work on genitourinary cancer, and has established cell lines and rare xenografts from primary human bladder and prostate tumours.

Most recently, her team has established new animal models for studies of bony metastases from prostate cancer, including those grown in immunocompetent mice, where interactions of growth factors common to bone cells and immune cells can be investigated.

Recent highlights by her team include production of a monoclonal antibody which binds 70% of prostate cancers, currently undergoing assessment for potential development as a diagnostic reagent and for targeted nanoparticle imaging; development of a first-in-man gene therapy for late stage prostate cancer, which is pending a Phase I clinical trial.

Prof Russell helped to establish the Animal Imaging Facility at The University of New South Wales for preclinical studies, and is now involved in the development of a preclinical imaging facility at the Australian Prostate Cancer Research Centre – Queensland to be part of the new Translational Research Institute, within the Princess Alexandra Biomedical precinct.

Prof Russell has received numerous prestigious awards over her career including: in 2003, Membership of the Order of Australia (AM) for her work on bladder and prostate cancer.

In 2006, she was awarded the Medal of Australia for contributions to bladder and prostate cancer research, as well as Life Membership in PCFA, and a prize for being an outstanding research alumnus of Sydney's Kolling Institute of Medical Research.

Prof Russell was made a life member of the Australasian Gene Therapy Society in 2009, and in 2010, she was named Prostate Cancer Researcher of the Year in Australia.

Dr Daniel Santa Mina
Postdoctoral Fellow, Princess Margaret Cancer Centre
Assistant Program Head, University of Guelph-Humber

Daniel Santa Mina is a Post-Doctoral Fellow at the Prostate Centre at the Princess Margaret Cancer Centre (Toronto, Canada) and the Assistant Program Head of Kinesiology at the University of Guelph-Humber (Toronto, Canada).

Dr Santa Mina is also a Certified Exercise Physiologist (Canadian Society for Exercise Physiology) and Cancer Exercise Specialist (RMCRI; University of Northern Colorado).

His research focus includes the effect of exercise during treatment for prostate cancer (specifically radical prostatectomy and androgen deprivation therapy), adherence to exercise in prostate cancer, the biological effect of exercise on prostate cancer cell proliferation, and trends in exercise programming for cancer patients.

He is the co-founder of the Survivorship Exercise Program at the Princess Margaret Cancer Centre, a clinical-research exercise program for prostate cancer survivors.

Ms Phoebe Sarkar
PhD Candidate
Australian Prostate Cancer Research Centre-Queensland
Institute of Health and Biomedical Technology
Queensland University of Technology
Translational Research Institute

After completing her BSc in biochemistry and health sciences at Simon Fraser University, Canada, Phoebe Sarkar joined the Australian Prostate Cancer Research Centre – Queensland in 2012.

She is currently working toward her PhD thesis and is the recipient of a QUT Postgraduate Research Award.

Her research investigates the molecular mechanisms driving insulin-induced migration and invasion in prostate cancer cells, particularly in the context of androgen deprivation.

Dr Luke Selth
Research Fellow
University of Adelaide

Dr Selth heads a group within the Dame Roma Mitchell Cancer Research Laboratories in Adelaide. His research focuses on two aspects of prostate cancer development and progression. The first involves research into the role of microRNAs in prostate carcinogenesis and metastasis and their use as potential biomarkers of disease. The second is aimed at investigating the mechanisms underlying continued androgen signalling in lethal forms of prostate cancer.

These research programs utilise contemporary genomic techniques to better understand prostate cancer at the molecular level. Dr Selth currently holds Young Investigator awards from both the US Prostate Cancer Foundation and the Prostate Cancer Foundation of Australia.

Dr Marketa Skala
Visiting Medical Specialist
Royal Hobart Hospital

Dr Skala's research focuses on genito-urinary malignancy, with particular emphasis on prostate cancer and new technology.

He is Chief investigator for an Australia-wide comparative study of Intensity Modulated Radiation Therapy (IMRT) prostate plans and was instrumental in formulating the Australia and New Zealand consensus guidelines for 3D conformal radiation therapy for prostate cancer in collaboration with the Faculty of Radiation Oncology Genito-urinary Group.

Dr Skala is also Principal investigator of the incidence of late toxicity following high-dose, image-guided radiotherapy for prostate cancer at Princess Margaret Hospital, and its correlation with dosimetric parameters.

He spearheaded the development of IMRT for the treatment of prostate cancer at the Nova Scotia Cancer Centre, Canada and introduced image-guided radiotherapy to the WP Holman clinic in Hobart, Tasmania.

Dr Carolina Soekmadji
Postdoctoral Fellow
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Dr Soekmadji joined the APCRC-Q in 2010 to investigate exosomes as prostate cancer biomarkers and the application of targeted nanoparticles to image prostate cancer, and subsequently received a US Department of Defense Postdoctoral Training Award for her project: Exosomes Biomarkers: defining prognosis for drug and castrate resistant prostate cancer.

After working at the University of Stuttgart in Germany on the design of a DNA microarray to detect bacteria, which cause pneumonia sepsis, she accepted an International Postgraduate Research Scholarship and Melbourne International Reseach Scholarship to study in Australia. There she completed her PhD in the Department of Genetics, at the University of Melbourne in 2009, investigating the role of the stoned protein family in exocytosis/endocytosis of synaptic vesicles.

Prior to joining APCRC-Q, she held a postdoctoral research position at the University of Queensland, investigating the involvement of dynamin in regulating the fusion pore dynamic and its role in the scission step during endocytosis of secretory granules in pancreatic acinar cells.

Dr Janet Stanford
Member, Division of Public Health Sciences
Fred Hutchinson Cancer Research Centre

Dr Stanford's work focuses on the epidemiology of prostate cancer, having completed many studies assessing lifestyle, environmental, and genetic risk factors for the disease, as well as outcomes research (predictors of function and quality of life after treatment, prostate cancer-specific mortality, and disease recurrence/progression).

She is Co-Investigator of the NCI/NIH-funded P50 grant, "Pacific Northwest Prostate Cancer SPORE" (Specialized Programs of Research Excellence), and leads one of the major SPORE research projects, "Genetic Susceptibility to Clinically Aggressive Prostate Cancer."

Dr Stanford is also a member of the International Consortium for Prostate Cancer Genetics (ICPCG), the PRACTICAL consortium, and the ELLIPSE consortium, all of which aim to advance knowledge of the genetic susceptibility to hereditary and sporadic prostate cancer. Her current research focuses on identification and validation of genetic and epigenetic biomarkers for aggressive prostate cancer.

Dr Sally Stephenson
Lecturer and Group Leader, Eph Receptor Biology Group
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Dr Stephenson is a Lecturer in the School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT). She is also Group Leader of the Eph Receptor Biology Group, part of the APCRC-Q and the Cancer Research Program within QUT's Institute of Health and Biomedical Innovation.

Her main research interest is the EphB4 receptor tyrosine kinase and the contribution that it makes to epithelial cancers including prostate cancer.

The Eph Receptor Biology Group is exploring (1) the consequences of over-expression of EphB4, (2) the sub-cellular localisation of the protein, (3) protease regulation of signaling, (4) activated intracellular signaling pathways and (5) the identification of interacting proteins.

The ultimate goal of this research is to identify new options for targeting this protein to provide options for the development of new anti-cancer therapies.

Dr Konstantin Stoletov
Research Associate
University of Alberta

Dr Konstantin Stoletov received his PhD from Albert Einstein College of Medicine, USA. He completed his postdoctoral training at the Scripps Research Institute and University of California, San Diego. He currently holds a Research Associate position at the University of Alberta, Edmonton, Canada.

His research interests include identification of novel targets and biomarkers to treat cancer metastasis and using intravital microscopy to visualize mechanisms of cancer cell dissemination.

Ms Nataly Stylianou
PhD Candidate
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Nataly Stylianou graduated from Queensland University of Technology (QUT) with a degree in Medical Science and continued her honours degree at the Institute of Health and Biomedical Innovation where she developed a novel inducible cell model to investigate the epithelial to mesenchymal transition (EMT) in prostate cancer cells.

Ms Stylianou is currently a PhD candidate at the Australian Prostate Cancer Research Centre – Queensland within QUT's Institute of Health and Biomedical Innovation where she is continuing her research in the EMT field.

In particular, she is interested in developing a series of novel cellular models to investigate EMT in a prostate cancer setting, and to further elucidate prostate cancer and its progression to castrate resistant prostate cancer and metastasis. Insights in these areas could lead to the identification of better therapeutic targets for prostate cancer.

Ms Julia Suurbach
PhD Candidate
Translational Cancer Research Group
University of Technology Sydney

Ms Suurbach completed her M.Sc. in Germany and is now a PhD student at the University of Technology Sydney's (UTS) Translational Cancer Research Group. She is the recipient of an International Postgraduate Research Award and a UTS President Award. Her work focus is on utilizing bone marrow derived mesenchymal stem cells as cellular vehicles to delivery therapeutic genes to advanced prostate cancer. Mouse models have been established to quantitate the efficacy of therapeutics and animal survival post cell implantation expressing therapeutics has been monitored. Her interests lie in stem cell harvest, stem cell behavior *in vitro* and *in vivo* and their potential as delivery vehicles for therapeutics.

Dr Renea Taylor
Research Fellow
Prostate Cancer Research Program
Department of Physiology
Monash University

Dr Taylor obtained her PhD from Monash University in 2003 and subsequently completed three post-doctoral training Fellowships supported by Cancer Council Victoria, US Department of Defense, and NHMRC (Peter Doherty Fellowship).

In 2008, she was awarded a Young Investigator Grant from the Prostate Cancer Foundation of Australia to establish her own research laboratory and in 2011 she took an academic position at Monash University in the Department of Physiology where she has a combined lecturing / research position.

Her research combines stem cell biology with models of prostate cancer in order to understand disease progression. She works within a multi-disciplinary network of scientists and clinicians, using human clinical specimens that allow her to make translational observations.

Dr Gregor Tevz
Postdoctoral Fellow
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

After receiving a Bachelor of Science of Microbiology from the University of Ljubljana, Dr Tevz took up a position as a research assistant at the National Institute of Chemistry Slovenia.

In 2005, Dr Tevz began his PhD, in Biomedical Sciences at the University of Ljubljana and Institute of Oncology Ljubljana.

Upon completion of his PhD, Dr Tevz joined European Initial Training Network Consortium for Prostate Cancer Research as a Postdoctoral Fellow at Philips Research in Netherlands.

He then travelled to Australia to join the Australian Prostate Cancer Research Centre-Queensland where his main research focus is progression of prostate cancer to castrate resistant disease and identification and development of new therapeutic targets.

Ms Laure Thibaudeau
PhD Candidate
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Laure Thibaudeau completed her studies in Materials Science and Engineering at the National Institute of Applied Sciences (INSA) of Lyon, France.

Since April 2011 she has been undertaking a PhD in Professor Hutmacher´s group within QUT's Institute of Health and Biomedical Innovation.

Her research project focuses on the development of a humanised xenograft model of breast cancer bone metastasis by applying a bone tissue engineering approach.

Mr Patrick Thomas
PhD Candidate
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

After completing a BSc in Medical Science at the Queensland University of Technology (QUT) in 2010, Mr Thomas moved on to complete his honours at QUT's Institute of Health and Biomedical Innovation where he investigated the role of reproductive hormones in breast cancer progression.

He is currently studying as a PhD student to continue research into hormones in cancer, with particular emphasis on the ghrelin hormone axis.

His research is investigating the role of a novel long non-coding RNA, GHSROS (growth hormone secretagogue receptor opposite strand), which is antisense to the ghrelin receptor gene and which has previously been shown to have a role in cancer progression. Identifying mechanisms of action and the role of GHSROS in prostate cancer could lead to a novel biomarker or antisense target for the diagnosis and treatment of prostate cancer.



Professor Wayne Tilley
Director Dame Roma Mitchell Cancer Research Laboratories
University of Adelaide

Prof Tilley is Director of the Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide and Hanson Institute, which incorporates more than 50 researchers and clinicians working on breast and prostate cancer.

Prof Tilley returned to Australia in late 1990 after an NHMRC CJ Martin Fellowship at UT Southwestern in Dallas, Texas where he was one of the first to clone the human androgen receptor (AR).

In 1997, he was appointed Director of the Flinders Cancer Centre.

Following a sabbatical in the Department of Preventive Medicine, the Norris Cancer Center, University of Southern California in 2002, Prof Tilley relocated to the University of Adelaide/Hanson Institute to take up the position of the Dame Roma Mitchell Chair in Cancer Research. Since that time he has developed a research program on hormone action in breast and prostate cancer, and played an integral role in the development of the Adelaide Prostate Cancer Cancer Research Centre and the Freemasons Foundation Centre for Men's Health.

Prof Tilley's laboratory has made a major contribution to understanding the molecular mechanisms of resistance to hormonal therapies used in the treatment of prostate cancer. In particular, his laboratory has shown that continued signalling via the AR is an important determinant of disease progression and treatment response in all stages of prostate cancer.

A current major research focus is the development of new treatments for prostate cancer that target the AR. Prof Tilley's laboratory has also pioneered research into understanding the pivotal role of AR in counteracting the proliferative effects of estrogens in the breast.



Dr Andrew Trotta
Postdoctoral Research Officer
University of Adelaide

Dr Trotta completed his undergraduate degree in Molecular Biology at The University of Adelaide in 2004, and his Honours degree from the Department of Obstetrics and Gyanecoloy in 2005.

He started a PhD in prostate cancer within the Department of Medicine in 2008 under the supervision of Dr Grant Buchanan and Professors Wayne Tilley, Gary Wittert, and Villis Marshall. His research focused on the role that tetratricopeptide repeat containing co-chaperone proteins play in regulating androgen receptor function. He completed his PhD studies in 2011.

Dr Trotta is currently a Postdoctoral research officer within Dr Buchanan's laboratory at the Basil Hetzel Institute and is focusing on identifying extracellular matrix and focal adhesion proteins that change with androgen regulation and cancer progression.

Dr Brian Tse
Postdoctoral Fellow
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Dr Tse was awarded his PhD from the University of New South Wales, Sydney, in 2011, for his work on developing novel forms of immunotherapy for prostate cancer.

He then undertook a two year postdoctoral position at the Lowy Cancer Research Centre, Sydney, where he studied the potential of anti-glycan antibodies as biomarkers of ovarian cancer, and on novel mechanisms of immune evasion in ovarian cancer.

Dr Tse joined the APCRC-Q in August 2012 and has been working on two projects: 1) Simultaneous Imaging and Drug Delivery for Prostate Cancer Theranostics, and 2) Mechanisms of Epithelial to Mesenchymal Transition in Prostate Cancer.

Dr Raja Vasireddy
Postdoctoral Fellow
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Dr Raja Vasireddy received his PhD from the University of Melbourne in 2010. He was the recipient of a Melbourne Research Scholarship for the duration of his PhD. Before moving into cancer research Dr. Vasireddy worked as a lecturer in India, teaching clinical microbiology to medical graduates. He completed his Masters degree in clinical microbiology from the University of Manipal, India. During his PhD he investigated the relationship between histone modifications, DNA damage and clinical radiation sensitivity.

After completing his PhD, Dr Vasireddy joined APCRC-Q and his current research interests include DNA damage response pathways, cell cycle regulation and radio and chemosenstisers in cancer therapy.

Ms Catalina Vasquez
Director
Alberta Prostate Cancer Research Initiative
University of Alberta

As the Program Director for the Alberta Prostate Cancer Research Initiative (APCaRI), Ms Vasquez is working to coordinate the translational goals of the team.

The APCaRI is comprised of multidisciplinary team of academic researchers, clinicians, nurses, and other personnel from universities, hospitals and biobanking centres across Alberta. With an overall goal improving outcomes and quality of life for those living with prostate cancer, the team is integrating its efforts to develop new diagnostic tests for prostate cancer, to discover novel biomarkers for aggressive prostate cancer, and to conduct clinical trials to establish the value of our new diagnostics in the clinic.

As a part of these efforts, Ms Vasquez will be coordinating the launch of a comprehensive biobank and database initiative called the Alberta Prostate Cancer Cohort. This ambitious prospective collection effort will serve as a validation cohort for diagnostic PCa tests under development by the team.

Prior to coming to Alberta, Ms Vasquez served as the Coordinator of the Lawson Translational Cancer Research Team and Project Manager for Investigator Initiated Trials with the Lawson Health Research Institute, London Health Sciences Centre and the Western University, where she also received her MSc in 2011.

During her Master's Degree, the focus of her research was to identify new biomarkers that could differentiate indolent vs. aggressive prostate cancer and mediators of cancer cell migration.

Mr Paul Villanti
Executive Director, Programs
Movember

Mr Villanti oversees and leads Movember's global investment in research and survivorship programs. He also serves as a Board Director at Movember, the Prostate Cancer Foundation USA, and is an Associate Director at The Prostate Cancer Charity (UK).

Dr Hoan Vu
Mass Spectrometry Research Fellow
Eskitis Institute
Griffith University

Dr Hoan Vu is a professional officer of the mass spectrometry facility at Eskitis Institute.

His research lines include identifying natural product fragments or lead-like enhanced fractions forming non-covalent complexes with prostate cancer protein targets, as well as developing mass spectrometry-based methods to identify binding sites of these active natural products.

Dr Amol Wagholikar
Project Leader and Research Scientist
Australian e-Health Research Centre
Commonwealth Scientific and Industrial Research Organisation (CSIRO)

An accomplished researcher and innovation consultant with unique expertise in technology innovation and decision support methods and strategies, Dr Wagholikar is currently working with APCRC-Q on collaborative research projects to improve understanding of advanced prostate cancer management through data-driven models and technology interventions for better health services delivery.

Dr Wagholikar has worked on variety of prostate cancer research projects ranging from developing ICT capability for advanced prostate cancer MDT clinic and developing health economic model for advanced prostate cancer. He has made a significant contribution in developing a new baseline health economics model for advanced prostate cancer. His particular objective is to add value in health services research for prostate cancer survivorship.

Dr Wagholikar also has extensive experience in technology innovation for better health services delivery and has been involved in various health services projects undertaken at Queensland Health and the Australian e-Health Research Centre, CSIRO. He has applied innovative decision support models and has led key research projects that addressed challenging research questions as well as business problems in health service delivery for prostate cancer as well as other diseases.

Dr Wagholikar's work on prostate cancer is published in high quality publications and he has presented his work in high quality conferences. He is also an active member of IEEE- Engineering in Medicine and Biology Society (EMBS) and is Chair of the IEEE EMBS chapter in Australia. Dr Wagholikar makes a voluntary contribution to IEEE Asia-Pacific region to promote technology awareness for better health delivery and has taught information technology and information systems courses in the universities for more than a decade at an under-graduate as well as post-graduate level as well as supervising research project students at Masters Level.

Ms Chenwei Wang
Postdoctoral Fellow
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

After receiving her Bachelor of Engineering, Computer Science from Xi'an University of Technology in China, Dr Wang worked as a software engineer for three and half years. In 2004, she was awarded a Master of Applied Science, Bioinformatics, from the University of Sydney, Australia, where she later went on to undertake her PhD in Bioinformatics. Her research focussed on linkage mapping, map integration, and comparative mapping of the Australian model marsupial tammar wallaby.

In 2010, Dr Wang took up a position as Research Officer at the Institute of Molecular Bioscience at the University of Queensland, in Brisbane, Australia. In this role, Dr Wang was responsible for conducting research in multi-focal prostate cancer microarray expression data, which involves data analysis using existing bioinformatics tools and programming. She also supervised students doing research projects on interologs of proteins in orthologous species.

In early 2012, Dr Wang joined APCRC-Q, where she is engaged in a multi-focal prostate cancer study using microarray expression data as well as comparative genomic hybridization (CGH) data from a cohort of 10 multi-focal prostate cancer patients.

Dr Kevin Wang
Research Officer
Centenary Institute

Dr Wang graduated with a Bachelor degree in the Department of Biophysics and Physiology at Fudan University in 1998. He obtained his PhD from Lens Research Laboratory at the University of Sydney in 2008, under the supervision of Associate Professor Frank Lovicu and Professor John McAvoy.

His PhD research examined MAPK and PI3K signalling pathways that involved in lens fibre cell differentiation. His postdoctoral research is supervised by Dr Jeff Holst and Professor John Rasko in the Origins of Cancer Laboratory and Gene and Stem Cell Therapy Program at the Centenary Institute. His study is focussed on the role and regulation of amino acid transporters and their related signalling pathways in prostate cancer.

As a Research Officer at the Centenary Institute Dr Wang draws on the Institute's strong international track record in amino acid regulation, to dissect how transporters including leucine transporters, may promote prostate cancer. He conducts these studies using prostate cancer cell lines and a prostate cancer mouse model crossed with a new knockout mouse model with the objective of analysing the genes involved in the onset and progression of prostate cancer.

POV1 transporter is a potential target for therapeutic intervention, and Dr Wang believes that understanding this complex network may provide new insights into the effect of diet (particularly red meats and dairy which are high in leucine) on the development and progression of prostate cancer.

Dr YZ Wang
Senior Scientist
Vancouver Prostate Centre
British Columbia Cancer Agency
Associate Professor, University of British Columbia

Dr Wang currently has a dual appointment as a Senior Scientist at Vancouver Prostate Centre and BC Cancer Agency, Canada. Dr Wang is also the Leader of the Living Tumour Laboratory and an Associate Professor at UBC. His living tumour laboratory (www.livingtumorlab.com) has developed over 150 transplantable tumour tissue lines that closely resemble patients' malignancies in terms of histopathology, genetic profiles and drug sensitivities. His current research focuses on applications of such xenograft models for the discovery and validation of potential biomarkers and/or therapeutic targets; preclinical drug efficacy studies in anti-cancer therapeutics development; and personalized cancer therapy.

In addition to proposing novel hypotheses on "prostate stem cells", "epithelial-immune cell transition (EIT)" and "cancer-generated lactic acid: a regulatory, immunosuppressive metabolite", Dr Wang is recognized for his pioneering work in the field of prostate cancer modelling. He was the first to establish tissue recombination model of hormonal prostatic carcinogenesis and he developed the first model of hormonal carcinogenesis in human prostatic epithelium. Moreover, he is responsible for a novel method for establishing transplantable, patient-derived xenograft models that closely resemble patients' malignancies. As a principal investigator, he is well funded by a number of funding agencies.

Presently, Dr Wang serves as an editorial member of the Cancer Biology & Medicine and ISRN Pathology. Dr Wang has received a number of awards for his academic achievements and since 1997 he has published over 90 peer-reviewed original articles and review papers.

Professor Bill Watson
Associate Professor of Cancer Biology
University College Dublin

Prof Watson received his PhD degree in Biochemistry from the Department of Biochemistry, University College Cork in 1995. He then undertook his post-doctoral research in University of Toronto and the Toronto General Hospital in Canada, before returning in 1997, to Ireland as a College Lecturer in the Department of Surgery, Mater Misericordiae University Hospital, University College Dublin.

Prof Watson is now an Associate Professor of Cancer Biology in the UCD School of Medicine and Medical Science. Apart from his undergraduate and post-graduate teaching responsibilities and programme co-ordinator of the Biomedical Health and Life Science Honours Degree programme, he has an active internationally recognised research group.

As a translational biologist, based in the Conway Institute, he utilises the latest technologies to study cellular and molecular pathways and clinical collaboration through the Prostate Cancer Research Consortium (of which he is a lead investigator and Chair of the Bio-resource management and implementation committee) to expand the understanding of the initiation and progression of prostate cancer in order to identify diagnostic and prognostic biomarker for prostate cancer as well as therapeutic sites for manipulation.

Prof Watson is Chair of the Basic Research Section of the European Association for Urology Research Foundation, Principal Investigator in the Molecular Medicine Ireland, and member of the Movember Global Scientific Advisory Committee.

Ms Sarah Wilkinson
Postdoctoral Research Fellow
Prostate Cancer Research Group
Monash University

Ms Wilkinson is a Postdoctoral Research Fellow in the Breast and Prostate Cancer Research Program, Monash University. She obtained her Bachelor of Science (Biomedical Science) Honours from Deakin University, Melbourne, in 2006. This project, for which she received first class honours, investigated the involvement of integrins in EMT and breast cancer metastasis.

Ms Wilkinson completed her PhD with Prof Gail Risbridger. During the first two years of her PhD, Ms Wilkinson published a paper in Stem Cells, which demonstrated the ability of the stroma to: (a) direct the differentiation of adult stems cell, and (b) trans-differentiate adult epithelial cells, both of which were from a different tissue type to that of the stroma. This was the first example of stromal mediated lineage epithelial lineage enforcement of epithelium from a different development germ layer origin to that of the stroma, and highlighted the importance of placing stem cells in the correct stromal niche when using them for regenerative medicine. Microarray analysis implicated a key role for stromal Hedgehog signalling (Hh) in the transformation process.

As Hh plays a key role in directing the differentiation of epithelium in prostate development, Ms Wilkinson has now turned her attention to the role of Hh in prostate epithelial transformation in cancer. Her current research is investigating whether active stromal Hh can initiate prostate cancer and whether the use of a pathway receptor antagonist can alleviate this phenotype.

Associate Professor Elizabeth Williams
Principal Research Fellow (Tumour Models)
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation, Queensland University of Technology
Translational Research Institute

Dr Elizabeth Williams, BSc (Hons), PhD, has worked in the field of cancer metastases, focussing on prostate and bladder cancer since completing her PhD in pharmacology in 1997. She joined APCRC-Q in 2013 to lead the tumour models stream and extend her prostate cancer research program.

Prior to joining APCRC-Q, Dr Williams was the Metastasis Research Group Leader at Monash Institute of Medical Research's Centre for Cancer Research (2006-2012), an Associate Senior Fellow at the Department of Surgery, University of Melbourne and a Research Fellow (Prostate Cancer Group Leader) at the Bernard O'Brien Institute of Microsurgery (2002-2006).

Dr Williams and her team have established a panel of systems to study the interaction of prostate cancer cells with the endothelial cells of the prostatic lymphatic vessels, with the aim of identifying key molecules involved in the process.

They are also investigating the molecular basis of prostate cancer cells that survive castration. Her current research project utilises a transplantable human prostate cancer xenograft that her team derived from a bone metastasis in 2001.

Dr Addie Wootten
Director of Clinical and Allied Health Research
Australian Prostate Cancer Research Centre Epworth

Dr Addie Wootten is a clinical psychologist and Director of Clinical and Allied Health Research at the Australian Prostate Cancer Research Centre - Epworth. In this role, she oversees the clinical trials, psychosocial research, and other allied health research conducted in the centre or collaboratively with other groups. As a psychologist, Dr Wootten's key research focus has been the psycho-social experiences of prostate cancer patients and their partners.

Dr Wootten is currently the principal investigator on a project co-funded by beyondblue and the Prostate Cancer Foundation of Australia, which is investigating the efficacy of an Internet-based psychological intervention for men with prostate cancer.

Dr Wootten was also recently awarded another research grant from BeyondBlue to develop and evaluate an online support program for partners of men with prostate cancer. Dr Wootten is the convener of the psycho-oncology meeting held as part of the Australasian Prostate Cancer Conference held annually.

As part of her clinical role Dr Wootten provides assessment and therapeutic interventions to individuals suffering a range of physical illnesses, particularly urological cancers. Dr Wootten works clinically with prostate cancer patients and their families across the cancer journey, from diagnosis to palliative care.

Dr Gaetano Zafarana
Research Associate
Princess Margaret Cancer Centre

Dr Gaetano Zafarana received his Honours Degree in Biochemistry and Molecular Biology from University College London.

During his undergraduate degree, he trained at the Biochemistry Department of Charing Cross Hospital, London, UK and the Ludwig Institute for Cancer Research, London, UK. He then moved to the National Institute of Medical Research, Mill Hill, London, UK to start his PhD on the regulation of the human embryonic b-globin genes.

He completed his Doctoral Thesis at the Department of Genetics and Cell Biology of the Erasmus Medical Centre in Rotterdam, The Netherlands, where he had relocated to follow his supervisor. He then moved to the field of Testicular Germ Cell Tumours for his first post-doctoral position at the Department of Pathology in the Josephine Nefkens Institute of the Erasmus Medical Centre, Rotterdam.

His second postdoctoral position brought him back to the UK at the Department of Biomedical Science, Centre for Stem Cell Biology, the University of Sheffield, where he applied his expertise to the field of human embryonic stem cells.

In 2009, Dr Zafarana moved to Toronto, Canada, where he manages the Core 1 of the STTARR facility at the Toronto Medical Discovery Tower, part of University Health Network. His current research interests include translational studies on the genetics of intermediate prostate cancers and the isolation and characterization of the stem cells of prostate cancer in view to improve and personalize the treatment of prostate cancer in patients.

Dr Amina Zoubeidi
Assistant Professor
Vancouver Prostate Centre
University of British Columbia

Dr Zoubeidi's major research focus is to uncover molecular mechanisms of prostate cancer progression to the castrate-resistant stage and metastatic disease with a special interest on elucidating mechanisms of epithelial mesenchymal transition.

She elucidates diverse mechanisms involving stress activated proteins, Hsp27, Clusterin, and tyrosine kinases Lyn and Fer in androgen independent progression.

Dr Zoubeidi recently developed pre-clinical models of Enzalutamide resistant tumours and cell lines and studying mechanisms of resistance to Enzalutamide including emergence of cancer like stem cells and neuroendocrine phenotype. She has an extensive expertise in cell signalling, molecular and cellular biology and *in vivo* efficacy studies.

Contact List

Dr Manuel Altamirano-Dimas
Postdoctoral Fellow
Vancouver Prostate Centre
manuel@prostatecentre.com

Dr Jiyuan An
Postdoctoral Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
j.an@qut.edu.au

Ms Kathryn Arthy
Australian Coordinator
Australian-Canadian Prostate Cancer Research Alliance
Centre Coordinator
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
kathryn.arthy@qut.edu.au

Professor Vicky Avery
Chief Investigator and Head
Discovery Biology
Griffith University
v.avery@griffith.edu.au

Ms Trish Ballario
Administration Officer
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
trish.ballario@qut.edu.au

Professor Bharati Bapat
Professor
University of Toronto
bapat@lunenfeld.ca

Dr Jyotsna Batra
Postdoctoral Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
jyotsna.batra@qut.edu.au

Dr Emma Beardsley
Clinical Fellow, Prostate Cancer Research Program
Monash University
Medical Oncologist, Frankston Hospital
Peninsula Health
emmabeardsley@hotmail.com

Dr Paul Boutros
Assistant Professor
University of Toronto
Principal Investigator
Ontario Institute for Cancer Research
Paul.Boutros@oicr.on.ca

Professor Robert Bristow
Clinician Scientist and Professor
Ontario Cancer Institute
Princess Margaret Cancer Centre
University of Toronto
rob.bristow@rmp.uhn.on.ca

Dr Grant Buchanan
Laboratory Head
University of Adelaide
grant.buchanan@adelaide.edu.au

Professor Ralph Buttyan
Senior Scientist
Vancouver Prostate Centre
Professor in Urologic Sciences
University of British Columbia
rbuttyan@prostatecentre.com

Dr Mark Buzza
Program Manager - Global Action Plan
Movember
mark@movember.com

Ms Mandy Chandler
Scientific Writer
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
mandy.chandler@qut.edu.au

Professor Simone Chevalier
Associate Professor
McGill Urology Director of Research
McGill University
simone.chevalier@mcgill.ca

Ms Ashlee Clark
PhD Candidate
Prostate Cancer Research Program
Monash University
ashlee.clark@monash.edu

Dr Jeremy Clark
Senior Research Associate
University of East Anglia
jeremy.clark@uea.ac.uk

Distinguished Professor Judith Clements
IHBI Cancer Program Leader
Scientific Director
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology,
Translational Research Institute
j.clements@qut.edu.au

Dr Niall Corcoran
Director of Translational Research
Australian Prostate Cancer Research Centre Epworth
University of Melbourne
niallmcorcoran@gmail.com

Professor Anthony Costello
Head, Department of Urology
Royal Melbourne Hospital
Executive Director
Australian Prostate Cancer Research Centre Epworth
Professorial Fellow
Department of Surgery, University of Melbourne
cosurol@bigpond.net.au

Ms Sally Crittenden
Business Development Manager
Australian Prostate Cancer Research
sally.crittenden@apcr.org.au

Dr Tanya Day
Postdoctoral Researcher
Adelaide Prostate Cancer Research Centre
University of Adelaide
Tanya.Day@adelaide.edu.au

Dr Elena De-Juan-Pardo
Senior Postdoctoral Research Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
elena.juanpardo@qut.edu.au

Associate Professor Marcel Dinger
Head for the Centre of Clinical Genomics
Garvan Institute of Medical Research
m.dinger@garvan.org.au

Dr Michael Doran
Group Leader - Stem Cell Therapies Laboratory
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
michael.doran@qut.edu.au

Dr Jonathan Dunne
Prostate Cancer Postdoctoral Fellow
Victoria University of Wellington
jonathan.dunne@vuw.ac.nz

Dr Stuart Ellem
Research Scientist
Prostate Cancer Research Program
Monash University
stuart.ellem@monash.edu

Professor Stephen Finn
Associate Professor of Pathology
University of Dublin, Trinity College
finns@tcd.ie

Dr Liesel FitzGerald
Research Fellow
Cancer Council Victoria
liesel.fitzgerald@cancervic.org.au

Dr Luc Furic
Research Fellow
Prostate Cancer Research Program
Monash University
luc.furic@monash.edu

Mr James Garland
Chief Executive Officer
Australian Prostate Cancer Research
james.garland@apcr.org.au

Mr Eli Gibson
PhD Candidate
Robarts Research Institute
University of Western Ontario
egibson@robarts.ca

Contact List

Ms Lauren Giorgio
PhD Candidate
Basil Hetzel Institute for Translational Research
University of Adelaide
lauren.giorgio@adelaide.edu.au

Dr Jennifer Gunter
Postdoctoral Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
jennifer.gunter@qut.edu.au

Professor Vanessa Hayes
Professor and Head of Human Comparative Genomics
Garvan Institute of Medical Research
v.hayes@garvan.org.au

Professor Adrian Herington
Associate Director IHBI (TRI)
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
a.herington@qut.edu.au

Dr Brett Hollier
Senior Research Fellow
Queensland Smart Futures Fund Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology,
Translational Research Institute
b.hollier@qut.edu.au

Dr Jeff Holst
Associate Faculty
Centenary Institute
j.holst@centenary.org.au

Dr Boris Holzapfel
PhD Candidate
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
borismichael.holzapfel@student.qut.edu.au

Mrs Nina Holzapfel
PhD Candidate
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
ninapauline.holzapfel@qut.edu.au

Associate Professor Chris Hovens
Scientific Director
Australian Prostate Cancer Research Centre Epworth
University of Melbourne
chovens@unimelb.edu.au

Dr Elizabeth Hovey
Senior Staff Specialist
Prince of Wales Hospital
Elizabeth.Hovey@sesiahs.health.nsw.gov.au

Professor Dietmar Hutmacher
Professor and Chair of Regenerative Medicine
Medical Device Domain Leader
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
dietmar.hutmacher@qut.edu.au

Dr Varinder Jeet
Postdoctoral Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
varinder.jeet@qut.edu.au

Dr Bill Jordan
Director, Centre for Biodiscovery
Victoria University of Wellington
bill.jordan@vuw.ac.nz

Dr Anthony Joshua
Clinician Scientist
Princess Margaret Cancer Centre
Anthony.joshua@uhn.ca

Dr Lidija Jovanovic
Postdoctoral Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
lidija.jovanovic@qut.edu.au

Dr John Lai
Postdoctoral Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
j2.lai@qut.edu.au

Dr Jacques Lapointe
Associate Professor
McGill University
jacques.lapointe@mcgill.ca

Dr Mitchell Lawrence
Postdoctoral Fellow
Prostate Cancer Research Program
Monash University
mitchell.lawrence@monash.edu

Mr Damien Leach
PhD Candidate
Basil Hetzel Institute for Translational Research
The University of Adelaide
Damien.leach@adelaide.edu.au

Dr Melanie Lehman
Postdoctoral Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
melanie.lehman@qut.edu.au

Miss Claire Levrier
PhD Candidate
Eskitis Institute
Griffith University
claire.levrier@griffithuni.edu.au

Dr John Lewis
Frank and Carla Sojonky Chair in Prostate Cancer Research
University of Alberta
jdlewis@ualberta.ca

Professor Paul Li
Department of Chemistry
Simon Fraser University
paulli@sfu.ca

Ms Michelle Liberio
PhD Candidate
Eskitis Institute
Griffith University
michelle.liberio@griffithuni.edu.au

Dr Patrick Ling
Senior Research Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
mingtat.ling@qut.edu.au

Dr Amy Lubik
Postdoctoral Fellow
Vancouver Prostate Centre
alubik@prostatecentre.com

Dr Geoff Macintyre
Postdoctoral Researcher
National ICT Australia (NICTA)
University of Melbourne

Dr Rose Martiniello-Wilks
Senior Lecturer and Head
Translational Cancer Research Group (TCRG)
School of Medical and Molecular Biosciences
University of Technology Sydney
Rosetta.Martiniello-Wilks@uts.edu.au

Dr Stephen McPherson
Postdoctoral Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
stephen.mcpherson@qut.edu.au

Mrs Erica Mohr
Senior Physiotherapist
Continence Advisory Services
Queensland Health
Erica_Mohr@health.qld.gov.au

Dr Lorelei Mucci
Associate Professor
Harvard School of Public Health
lmucci@hsph.harvard.edu

Contact List

Dr Eleanor Need
Hospital Research Foundation
Early Career Research Fellow
Basil Hetzel Institute for Translational Research
University of Adelaide
Eleanor.need@adelaide.edu.au

Professor Colleen Nelson
Executive Director
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
colleen.nelson@qut.edu.au

Dr Christopher Ong
Senior Scientist
Vancouver Prostate Centre
chris.ong@ubc.ca

Professor Klaus Pantel
Professor and Director
Department of Tumor Biology
University Medical Center Hamburg-Eppendorf
pantel@uke.de

Dr Robert Paproski
Postdoctoral Fellow
University of Alberta
robertpaproski@hotmail.com

Dr Ngoc Pham
Research Fellow
Eskitis Institute, Griffith University
N.Pham@griffith.edu.au

Dr Lisa Philp
Postdoctoral Research Fellow
Adelaide Prostate Cancer Research Centre
University of Adelaide
lisa.philp@adelaide.edu.au

Dr Ruth Pidsley
Postdoctoral Researcher
Garvan Institute of Medical Research
r.pidsley@garvan.org.au

Ms Kim Rasmussen
Communications Coordinator
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
k.rasmussen@qut.edu.au

Mr Richard Rebello
PhD Candidate
Prostate Cancer Research Program
Monash University
richard.rebello@monash.edu

Dr Paul Rennie
Director of Laboratory Research
Vancouver Prostate Centre
Professor, Urologic Sciences
University of British Columbia
prennie@prostatecentre.com

Professor Gail Risbridger
Head, Prostate Cancer Research Group
Deputy Dean-Strategic Projects
Faculty of Medicine, Nursing and Health Sciences
Research Director
Monash Comprehensive Cancer Consortium
Monash University
Gail.Risbridger@med.monash.edu.au

Dr David Rivest-Henault
Postdoctoral Fellow
Australian e-Health Research Centre, CSIRO
david.rivest-henault@csiro.au

Dr Daniel Santa Mina
Postdoctoral Fellow, Princess Margaret Cancer Centre
Assistant Program Head, University of Guelph-Humber
daniel.sta.mina@uhn.on.ca

Ms Phoebe Sarkar
PhD Candidate
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
phoebelorraine.sarkar@student.qut.edu.au

Dr Luke Selth
Research Fellow
University of Adelaide
luke.selth@adelaide.edu.au

Dr Marketa Skala
Visiting Medical Specialist
Royal Hobart Hospital
Marketa.skala@dhhs.tas.gov.au

Dr Carolina Soekmadji
Postdoctoral Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
carolina.soekmadji@qut.edu.au

Dr Janet Stanford
Member, Division of Public Health Sciences
Fred Hutchinson Cancer Research Center
jstanfor@fhcrc.org

Dr Sally-Anne Stephenson
Lecturer and Group Leader, Eph Receptor Biology Group
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology, Translational Research Institute
s.stephenson@qut.edu.au

Dr Konstantin Stoletov
Research Associate
University of Alberta
kstoletov@gmail.com

Ms Nataly Stylianou
PhD Candidate
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
nataly.stylianou@qut.edu.au

Ms Julia Suurbach
PhD Candidate
Translational Cancer Research Group
University of Technology Sydney
jsuurbach@gmail.com

Dr Renea Taylor
Research Fellow
Prostate Cancer Research Program
Monash University
renea.taylor@monash.edu

Dr Gregor Tevz
Postdoctoral Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
gregor.tevz@qut.edu.au

Miss Laure Thibaudeau
PhD Candidate
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
laure.thibaudeau@qut.edu.au

Mr Patrick Thomas
PhD Candidate
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
pb.thomas@qut.edu.au

Professor Wayne Tilley
Director
Dame Roma Mitchell Cancer Research Laboratories
University of Adelaide
wayne.tilley@adelaide.edu.au

Dr Brian Tse
Postdoctoral Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
brian.tse@qut.edu.au

Dr Raja Vasireddy
Postdoctoral Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
raja.vasireddy@qut.edu.au

Ms Catalina Vasquez
Director, Alberta Prostate Cancer Research Initiative
University of Alberta
catavasher@gmail.com

Contact List

Dr Hoan Vu
Mass Spectrometry Research Fellow
Eskitis Institute, Griffith University
hoan.vu@griffith.edu.au

Dr Amol Wagholikar
Project Leader and Research Scientist
Australian e-Health Research Centre, CSIRO
amol.wagholikar@csiro.au

Ms Chenwei Wang
Postdoctoral Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
chenwei.wang@qut.edu.au

Dr Kevin Wang
Research Officer
Centenary Institute
k.wang@centenary.org.au

Dr YZ Wang
Senior Scientist
Vancouver Prostate Centre, British Columbia Cancer Agency
Associate Professor, University of British Columbia
ywang@bccrc.ca

Professor William Watson
Associate Professor of Cancer Biology
University College Dublin
william.watson@ucd.ie

Dr Sarah Wilkinson
Postdoctoral Research Fellow
Prostate Cancer Research Group
Monash University
sarah.wilkinson@monash.edu.au

Associate Professor Elizabeth Williams
Principal Research Fellow (Tumour Models)
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Translational Research Institute
ed.williams@qut.edu.au

Dr Addie Wootten
Director of Clinical and Allied Health Research
Australian Prostate Cancer Research Centre Epworth
addie.wootten@apcr.org.au

Dr Gaetano Zafarana
Research Associate
Princess Margaret Cancer Centre
gaetano.zafarana@rmp.uhn.on.ca

Dr Amina Zoubeidi
Assistant Professor
Vancouver Prostate Centre
University of British Columbia
azoubeidi@prostatecentre.com